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Abstract
Savan V. Patel
DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES: (I) TARGETING
ALLERGIC RESPONSES TO PEANUTS AND (II) INHIBITION OF DPP-IV
ENZYME INVOLVED IN DIABETES
2016 - 2017
Catherine F. Yang, Ph.D.
Master of Science in Pharmaceutical Sciences

There is an increase in prevalence of peanut allergy, especially in the western
world. The only current treatment for peanut allergy is avoidance of peanut from diet and
contact. Additionally, there is currently no specific vaccine that can be taken to decrease
peanut allergies. The method of desensitizing a person allergic to peanut allergy is deemed
unsafe as the smallest amount of peanut can trigger an anaphylaxis reaction. Thus, various
allergoids were created by modifying major peanut protein allergen Ara h2 using various
cross-linkers and modification agents in order to disrupt the binding surface epitopes of the
antigen to antibody.
Diabetes is also a growing problem that affects millions of people globally. Having
diabetes is known to lead to various morbidity as well which can be detrimental to the
patient and a burden to the economy. Various drugs are available as monotherapy for
diabetes; however, we aimed to develop dual acting compounds that would not only control
type 2 diabetes but also commonly associated diagnosis of hypertension as well. Thus, we
have successfully synthesized and tested compounds in vitro as effective dipeptidyl
peptidase-IV (DPP-IV) inhibitors and potentially effective in treating hypertension (future
study) associate with diabetes by utilizing cyanopyrrolidines and β-amino alcohols
scaffolds in the structure, respectively.
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Chapter 1
Understanding Allergens in Peanuts
Introduction
Species of peanut. Peanuts are widely used around the world for their source of
high quality protein and oil content. World production of peanut is about 30 million metric
tons per year with China, India and U.S. producing 13.4, 7.7 and 1.8 million metric tons,
respectively. Just for comparison to see the utilization and importance of peanuts, the
global corn production in year 2004/2005 was 706 thousand metric tons out of which U.S.
produced about 300 thousand metric tons of corn. Seven states in the U.S. account for 99
percent of all peanuts grown. Georgia produces the largest (41%), followed by Texas
(24%), Alabama (10%), North Carolina (9%), Florida (6%), Virginia (5%) and Oklahoma
(5%). Peanuts are used as value-added product in numerous applications which include but
not limited to peanut flour, peanut oil, roasted peanuts and peanut butter.1 Despite such
high usage of peanuts, the prevalence of peanut allergy is becoming a growing concern in
the westernized world thus making them an important plant seed of study.2-7
Peanuts are different from other tree nuts like almonds and walnuts because they
produce their seeds just below the ground. Peanuts are of the genus Arachia, species
Arachis hypogaea, which is a member of the legume family (Fabaceae) dating back to
2000-3000 B.C. in the Peruvian excavations.8 Peanut species A. hypogaea is divided into
two subspecies, hypogaea (hypogaea hypogaea) and fastigiata (fastigiata vulgaris and
fastigiata fastigiata), commonly called Virginia, Spanish, and Valencia, respectively.
There is a hybrid between subspecies of Virginia and Spanish called Runner.9 Runners are
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the dominant peanut type grown in U.S. (80% of total U.S. production) since they provide
the most yield and are used to make the most eaten style of peanut in U.S., peanut butter.
Virginia peanuts (account for about 15% of total U.S. production) have the largest kernels
and sold predominantly as roasted peanuts in their shells. Spanish peanuts (account for 4%
of U.S. production) have a smaller kernel with reddish-brown skin with highest oil content
than other types of peanuts. Valencia peanuts (account for less than one percent U.S.
production) have three or more small kernels per pod and are very sweet sold in shell, or
eaten boiled.1
Although there were numerous different types of species, subspecies and varieties
of peanut in the beginning and middle of the 20th century, the only cultivars used for
breeding now are Virginia, Spanish, and Valencia. Runner, although it is a hybrid, is also
considered a cultivar since it has been in use for a long time.9 Thus, it is important to focus
on these different varieties as they are the most used around the world. It has been shown
by Sheppard and Rudolf10 that the four different peanut types have no significant
differences in fat, ash or protein content. Approximately 90% of total fatty acid content of
peanut oil is composed of 10% palmitic acid and 80% oleic and linoleic acid. Runner and
Virginia type showed similar oleic and linoleic acid content than Valencia and Spanish
subspecies.10 Peanut seeds in general contain about 44-56% oil content and about 24-29%
protein content across various types of peanuts.9,11 Along with same protein content, the
amount of protein that is extractable is about the same among different peanut varieties as
well.9
Proteins that elicit allergic reaction from peanuts, specifically Ara h2. Since
mostly proteins are responsible for mediating allergic reaction, it is important to focus on
2

the different types of allergens in the peanut seed. Currently up to date, World Health
Organization (WHO) and International Union of Immunological Societies (IUIS) Allergen
Nomenclature Subcommittee have identified 16 different peanut allergens that are capable
of eliciting allergic reactions with the exception of Ara h4 which is now classified and
termed as Ara h3.02 under Ara h3 family. The allergens are classified from Ara h1 to Ara
h17 with their biochemical name as shown in Table 1 below.12

Table 1
List of major allergens of peanut and its corresponding protein family name and molecular
weight as resolved by SDS-PAGE.

Note: Obtained from allergen.org which is managed by IUIS Allergen Nomenclature
Subcommittee.
(http://allergen.org/search.php?allergensource=peanut&searchsource=Search)
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The protein super families are cupin (Ara h1, Ara h3, Ara h3.02), the prolamin (Ara
h2, Ara h6, Ara h7, Ara h9, Ara h16, Ara h17), the profilin (Ara h5), the Bet v 1 (Ara h8),
the glycosyl transferase GT-C (Ara h10, Ara h11, Ara h14, Ara h15), and the scorpion
toxin-like knottin (Ara h12, Ara h13).11 Proteins are classified as such due to their
similarity in structure and sequence to the superfamilies. The cupin allergen Ara h1 is a
member of vicilins or 7Sglobulins which are characterized as lacking cysteine residues and
by disk-shaped trimeric proteins whose subunit vary due to posttranslational proteolytic
processing and glycosylation. The other cupin protein Ara h3 is from legumin or 11S
globulins family which are hexameric proteins that are linked by a single disulfide bond.
The prolamin superfamily are characterized by containing eight cysteine residues but have
very little to none sequence similarity. The 3-dimensional structure consists of bundles of
four α-helices stabilized by disulfide bonds.11 Other protein superfamilies are important;
however, the most allergenic groups are cupin and prolamin, specifically allergens Ara h1
and Ara h2 as described below.
Out of the 17 different peanut allergens, Ara h1 and Ara h2 have been found to be
the most potent in eliciting allergic reaction.13,14 The reason they are categorized as a major
peanut allergen is because they are recognized by greater than ninety percent IgE of peanut
allergic patients.9,13-15 IgE is short for immunoglobulin E which are responsible for
protecting the body from foreign substances (talked below in section “peanut as an
allergen”). Ara h3 is sometimes identified as a major or minor allergen depending on the
population sample with a range of 44-77% of IgE mediated reaction in peanut allergic
population.16 Another definition of major peanut allergen is proteins that are responsible
for a majority of effector activity of food rather than just IgE recognition. Effector activity
4

is referred to the ability of an allergen to effectively cross-link IgE and activate mast cells
and basophils since this is clinically relevant, and according to this definition, Ara h2 and
Ara h6 have been found as major peanut allergens in crude peanut extracts.17,18
Most protein from the peanut seed is stored in the protein superfamilies’ of cupin
or prolamin of peanut. The cupin Ara h1 was determined by Koppelman et al.9 to be 1216% of total protein content and the 2S albumin Ara h2 to be 5.9-9.3% of total protein
content in peanut. All of the classes combined account for 85% of total peanut protein
while Ara h1, Ara h2 and Ara h3 together account for 75% of total protein content.11 Study
by Koppelman et al.9 concluded that differences in serology between peanut allergic
patients from different parts of the world are not explained by the allergen composition of
different peanut types. Thus, a focus on the different protein allergens from peanut seed
are of importance, particularly Ara h2.
It has been found that Ara h2 has peptide sequences that are similar to peptides in
Ara h1 and Ara h3, which helps to explain co-sensitization to the three major allergens
even though the structure, sequence, and protein groups are not similar.19 It has been shown
that Ara h2 is resistant to further enzymatic fragmentation after treatment with trypsin,
chymotrypsin, or pepsin. The remaining large fragments are shown to contain intact IgEbinding epitopes which makes Ara h2 a very potent allergen.20
This research is specifically on the protein Ara h2 since it is found to be the most
potent allergen via IgE recognition and as a major effector activity of peanuts.17,21 Ara h2
is found to have two classes of protein isoforms (2.01 with 18.0 kDa and 2.02 with 17.7
kDa) which vary with addition of a 12-residue sequence in the flexible loop region of the
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protein structure.22,23 Native Ara h2 consists of 31% α-helix, 10% β-strand, and 59%
random coil and/or loops; roasted Ara h2 consists of 29% α-helix, 12% β-strand, and 59%
random coil and/or loops.24 Ara h2 is a monomeric protein with 5 helices and 8 cysteine
residues that form 4 disulfide bonds with at least one disulfide bond connecting each helix
to another.25 The disulfide bonds are important in stability of the secondary structure and
maintaining allergenicity. A 3D molecular model of Ara h2 can be seen in Figure 1 that
was created using VMD software.26 Ara h2 is found to be a weak trypsin inhibitor (trypsin
binding residues 76 to 85) whose activity is enhanced by 3.5-fold due to roasting. Ara h1
is known to under go degradation by trypsin, however, Ara h2 being a weak trypsin
inhibitor, it protects Ara h1 and increases potency of Ara h1 in roasted peanuts.24
It is important to be able to recognize important IgE-binding epitopes of Ara h2
since they can further help shed light on the therapeutic approaches to peanut
hypersensitivity to prevent anaphylaxis and potentially desensitize patients. Ara h2
contains 157-amino acids and within the protein there are 10 IgE-binding epitopes. Three
epitopes are found between aa17-39, four epitopes between aa41-80 and three epitopes
between aa114-157. These 10 IgE-binding epitopes include 63% amino acids that are either
polar uncharged or apolar residues. Out of the 10 IgE, there are 3 immunodominant IgE at
aa27-36, aa57-66, and aa65-74. It was shown that even one amino acid modification from
the immunodominant IgE epitopes significantly decreased IgE binding.15
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Figure 1. Molecular modeling of Ara h2 protein using VMD software. Note: non-polar
residues (white), basic residues (blue), acidic residues (red) and polar residues (green).26

7

Peanut as an allergen. Despite such heavy use of peanuts by the world and a long
history of cultivation, peanut allergies are on the rise. Research on food allergy has been
discussed in scientific literature as early as 1912 with the first major peanut allergen to be
documented and named (Ara h1) in 1991.14,27 Not just peanut allergies but allergies to food
have been increasing in the westernized countries. Although any food can cause an allergic
response, the most common are milk, eggs, fish (e.g., bass, flounder, cod), crustacean
shellfish (e.g., crab, lobster, shrimp), tree nuts (e.g., almonds, walnuts, pecans), peanuts,
wheat and soybeans. According to the Food Allergen Labeling and Consumer Protection
Act (FALCPA) of 2004, it is mandated that these eight major allergens be labelled in foods
that contain these declared major food allergens. These common allergies account for 90%
of all food allergies.28,29
According to guidelines for the diagnosis and management of food allergy in the
U.S., food allergy is defined as “an adverse health effect arising from a specific immune
response that occurs reproducibly on exposure to a given food.” Immune related food
allergy can be IgE mediated, non-IgE mediatd, Mixed IgE and non-IgE mediated, or cell
mediated. Non-immune related adverse reaction to food can be metabolic, pharmacologic,
toxic or idiopathic/undefined in relation so it is important to properly identify the allergen
according to guidelines for food allergy management. Foods that do elicit reproducible
adverse reactions but not linked immunologically are not considered food allergens and
instead are called food intolerances (e.g. lactose intolerance).2
Peanut allergy is IgE-mediated and there are two stages in the development of an
IgE-mediated allergy. Upon first exposure to the allergen, sensitization stage occurs. When
an allergen is consumed, gastric acid and digestive enzymes break down the protein that
8

are then exposed to mucosal immune system in gastrointestinal tract. This exposure causes
plasma cells to produce allergen-specific IgE (a-sIgE) to the peptide fragment that was
exposed on the allergen. This a-sIgE then attaches to mast cells and basophils via FcεRI
receptors, concluding the first stage.27
The second stage, allergic reaction, is initiated upon second exposure to peanuts,
specifically peanut protein and their peptide fragment containing epitopes. These allergens
then bind to and cross-link two or more IgE-FcεRI complexes that are on the surface of the
mast cells or basophils resulting in basophil or mast cell degranulation and subsequent
release of various inflammatory mediators, such as cytokines, chemokines, lipid mediators,
and histamines. These chemicals cause a series of local symptoms, such as itching,
swelling, nausea/vomiting, and diarrhea, in addition to various systemic symptoms, such
as airway obstruction, hives, low blood pressure, and even fatal anaphylaxis.27,30
The most common types of allergies among children are food or digestive allergies,
skin allergies such as eczema, and respiratory allergies such as hay fever. There has also
been an increase in prevalence of skin allergies among children as well. Children with skin
allergies went from 7.4% in 1997-1999 to 12.5% in 2009-2011. There is no significant
trend in respiratory allergies from 1997-1999 but from 2009-2011, the prevalence rate has
been 17%.31
Although peanuts contain approximately the same protein content across different
varieties, there is a difference in prevalence of peanut allergies across different parts of the
world.9 There have been many theories postulating why the prevalence of peanut allergy is
increasing in the western world over the last decade. The theories include; imbalance
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between the T-helper 1 (Th1)/T-helper 2 (H2)-biased cellular responses in early life,
exposure of peanut allergens in breast milk of lactating women sensitizing the infant,32
preparation of peanut (dry roasting in U.S. and other western countries), family history of
peanut allergy, consumption of soy during infancy along with onset of skin allergies and
exposure to topical preparations (e.g. treatment for anti-rash, eczema, dry skin, etc.)
containing peanut oil.2,24,29 On the contrary, it has been shown by Du Toit et al.6 through
their Learning Early about Peanut Allergy (LEAP) trial that early introduction of peanuts
significantly decreased the frequency of the development of peanut allergy among children
at high risk for this allergy and modulated immune responses to peanuts.
One study by Du Toit et al.33 was able to show that early introduction of peanut in
infants’ diet relates to a decrease and ultimately prevention of development of peanut
allergy. They studied prevalence of Jewish children living in UK and living in Israel. The
reason for this group of children that were studied was that children in Israel were fed
peanut within the first year of their life and children in UK had avoidance of peanut till
later age. The results showed a 10-fold higher prevalence of peanut allergies in Jewish
children living in UK versus Jewish children in Israel.33 This goes to show that the
guidelines recommending avoidance of peanuts during infancy is rather incorrect and that
actually an early exposure is better to preventing peanut allergies.6
Unfortunately, the current treatment for food allergy is avoidance of that food
allergen. In an incidence of accidental ingestion of allergen, prompt administration of
epinephrine is recommended to treat anaphylactic reaction.2 Peanuts and other tree nuts
have shown to be persistent allergen with lowest amount of resolution as the children ages
among the common allergens. Study by Skolnick et al.34 demonstrates that about 21.5% of
10

children outgrown their peanut allergy and that children with low peanut IgE levels should
be offered a peanut challenge in a medical setting to demonstrate if they can now tolerate
peanuts. For comparison, children with allergies to egg and milk is resolved by 11% and
19%, respectively, by age 4 years and that about 80% of these allergies are resolved by age
16 years.5 Due to consistency of peanut allergies in children and as adults, it is of the most
important allergy to be studied and focused on.
The average number of food related incidence per year in the U.S. shows 125,000
emergency department visits and 53,700 episodes of anaphylaxis.5 Food-induced
anaphylaxis occurred every 5 minutes in the U.S. between years 2001 and 2005 with nearly
one-half million emergency department visits.35 The annual incidence rate of children with
food allergy is at 14.3% and surprisingly 85% of these children attended schools
prohibiting peanuts.36 Food allergies are an important concern for U.S. as they impact the
economy. The overall economic cost of food allergy was estimated at $24.8 billion
annually, which is about $4184 per year per child. Direct medical costs are estimated to be
$4.3 billion annually, costs borne by the family totaled $20.5 billion annually, lost labor
productivity costs totaled $0.77 billion annually, out-of-pocket costs totaled $5.5 billion
annually and opportunity costs totaled $14.2 billion annually. The caregivers reported a
willingness to pay $20.8 billion annually which is $3504 per year per child for food allergy
treatment.37 Clearly, there is a significant medical cost to having food allergy that is bared
by the U.S. health care system and even more so by families with a food allergic child.
The adverse immune responses to foods affect approximately 15 million people.4,38
Out of the 15 million people, an estimated 9 million or 3-4% are adults who have food
allergies.5 A 2008 CDC prevention report indicated an 18% increase in children food
11

allergy from year 1997 to 2007, with an estimated 3.9% of children currently affected.
Specifically, for peanut allergy in the U.K. and U.S., the prevalence rates have essentially
doubled for children exceeding 1%.5 Looking at 11-year follow-up study by Sicherer et al.7
showed prevalence of peanut allergy in children in 2008 to be 1.4% compared with 0.8%
in 2002 and 0.4% in 1997.
However, a more recent study completed by Gupta et al.38 suggests that the
prevalence and severity of childhood food allergy is greater than in previously reported
studies. Gupta et al.38 suggests that food allergy prevalence is actually 8.0% rather than
3.9% in children, which is nearly 5.9 million affected children in U.S. With no surprise,
the prevalence among all children (without food allergy) surveyed for all ages showed
peanuts (2.0%) to be the highest prevalence frequency followed by milk (1.7%), shellfish
(1.4%), tree nut (1.0%), egg (0.8%), fin fish (0.5%), wheat (0.4%) and soy (0.4%).
Prevalence among children (with food allergy) surveyed showed peanuts (25.2%) to be the
highest followed by milk (21.1%), shellfish (17.2%), tree nut (13.1%), egg (9.8%), fin fish
(6.8%), wheat (5.0%) and soy (4.6%).38
Gupta et al.38 also conducted a study to evaluate the history of severity of common
food allergies among affected children. Severe reaction was seen in 38.7% of affected
children and mild-to-moderate reaction in 61.3% of affected children. Children who had
multiple food allergies accounted for 2.4% of all children corresponding to 30.4% of
children with food allergy. Needing further studies, Hispanic children have lower rates for
food allergies than non-Hispanic white and black.31,38 There are socially constructed
disparities that suggest difference in prevalence of food allergy by race and income.38
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Modification of Ara h2 as a potential immunotherapy stimulant. Proteins of
peanut allergens are generally stable under high pressures, varying temperatures and
digestive conditions.20,39 One of the reasons for this is roasting the peanut which causes
modification of lysine and possibly arginine residues by the Maillard reaction.40 The
Maillard reaction is a nonenzymatic chemical modification between amino acids and
reducing sugars when cooked at high temperature to form advanced glycation end-products
(AGEs).41 Roasting induces protein structural changes that enhance allergenic properties
of Ara h1 and Ara h2. The Maillard reaction explains stability of other food allergens as
well in that it preserves protein structure and IgE-binding epitopes rendering them from
digestion by specific peptides in the digestive tract.40,42 Thermal treatment also results in
formation of variety of advanced glycation end products which increases the weight of the
allergen. The increased weight of an allergen can potentially make the allergen more potent
since the digestive enzymes are not able to access the cleavable sites.22,43
It has been shown that boiling or frying of peanut matrix, as practiced in China,
reduces the allergenicity of peanuts.44 This could explain why the prevalence of peanut
allergy is increasing in the western world where roasting peanuts is more common
compared to countries where peanuts are commonly prepared by boiling or frying such as
China. Since most of the peanuts eaten in U.S. are in the form of roasted peanuts, it was
important for us to use roasted peanuts in the development of an allergoid as potential
therapeutic.
There has been evidence of modification of IgE-binding epitope of peanut allergen
to decrease serum IgE binding from peanut-hypersensitive patients and stimulate T-cell
proliferation and activation.45-47 It has been studied that no specific epitopes were
13

associated with severe reactions to peanut and that clinical sensitivity is positively related
to a more polyclonal IgE response.48 King et al.45 were able to engineer a mutant Ara h2
that showed less binding to allergen-specific IgE which was able to interact with T-cells
and release significantly lower amounts of mediators from passively sensitized mast cells
thus lowering allergenicity. Another option to reduce allergen-specific IgE is to mask
allergen epitopes by crosslinking protein via specific amino acid. Wu et al.47 were able to
crosslink Ara h2 (either inter- or intramolecular) at tyrosine using polyphenol oxidase as
catalyst. This allowed crosslinked Ara h2 to be more digestible by gastric fluid (however
more difficult to digest by intestinal fluid) and a decrease in allergenicity was noted since
three of the five tyrosine that were crosslinked were located in two of three main epitopes
of Ara h2.47 Another study showed the combined effects of polyphenol oxidase and caffeic
acid, a phenolic compound, leading to decreased IgE binding of Ara h1 and Ara h2 by
cross-linking via tyrosine residues of protein 1 and protein 2.49-51
There are various immunotherapies in the market for various pollen like ragweed
or venom anaphylaxis such as wasp allergy but there is no FDA approved immunotherapy
for food allergies.27 There has been a study done by Nelson et al.52 where they injected
peanut extract into patients with peanut allergy using subcutaneous immunotherapy
(SCIT). Their study concluded that due to over reaction in patients upon injection of peanut
allergen that a modified peanut extract is needed instead of unmodified. This has opened
doors to antigen-specific approaches to decreasing peanut allergenicity which include oral,
sublingual, and epicutaneous immunotherapy.53
Oral immunotherapy (OIT) delivers antigens to the mucosal immune system via
ingestion with absorption through the small intestine. OIT has been recently recognized
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clinically to desensitize patients to peanut with suppression of mast cell and basophile
activation along with increase in blocking peanut-specific IgG and IgG4 antibodies which
compete with IgE for the binding of peanut proteins.54 These studies have been
demonstrated in European countries as well such as Germany and England, however, OIT
is still deemed as an experimental treatment and not ready for widespread
implementation.27
Sublingual immunotherapy (SLIT) delivers antigens to the oral mucosa by placing
protein under the tongue. A recent study by Burks et al.55 was able to conclude that SLIT
was able to desensitize peanut allergic patients with decreased immunologic activity over
3 years along with excellent long-term safety profile. By the end of the study, 10.8% of
patients were fully desensitized to 10 g of peanut powder, however, more than 50%
discontinued therapy by the end of year 3.55
Another approach is epicutaneous immunotherapy (EPIT) which uses spray-dried
allergens on a membrane applied to patient’s skin. The superiority of this therapy over OIT
and SLIT is that the effect of peanut allergy is localized to the area of the patch and not
systematic. A current treatment in clinical trials is Viaskin Peanut, which showed peanut
EPIT administration was safe with reduced sensitivity to peanut and increased IgG4 levels
and IgG4/IgE ratio along with reduced basophil activation and peanut-specific TH2
cytokines. This study was after 52 weeks of treatment which showed higher success among
younger children of age 4-11.56
There are also non-antigen-specific approaches which involve administration other
than the allergen to decrease allergenicity. There has been many anti-IgE therapy like
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monoclonal antibody against human IgE, TNX-901 and antihuman IgE monoclonal Xolair
(FDA approved but later discontinued) which have shown effectiveness by decreasing
circulating IgE towards allergens and treating asthma, respectively. These anti-IgE
therapies maybe impractical as they are expensive with lifelong injections to decrease
continuous IgE proliferation in the body. There is an immunomodulatory phytochemicals
category as well which are small molecules extracted from plants. This type of therapy has
shown promise as a Chinese medicine called food allergy herbal formula-1 (FAHF-1),
which contains 11 herbal extracts and FAHF-2 containing 9 herbal extracts in treatment of
food allergy. FAHF-2 has been shown to decrease peanut, egg and fish allergy in murine
study with no human trials. Recent study of FAHF-2 in human showed favorable in vitro
immunomodulatory effects however with no improvement of tolerance to food allergens.57
The future goal of this study in creating a modified Ara h2 protein is so that it can
be utilized in OIT or for some patients allergic to peanut, SIT since it offers a long lasting
clinical efficacy as well.58 The problem with using OIT or SIT to desensitize patient with
peanut allergy is that the peanut proteins (especially Ara h2) are very potent leading to high
risk of systemic adverse events such as anaphylaxis as show back in a study back in 1997.52
Thus, if Ara h2 can be modified in a way to either mask or disrupt epitope binding amino
acids, it can be used in a controlled dosage form to desensitize patient with peanut allergy,
which is the goal of this part of the thesis.
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Chapter 2
Purification of Ara h2 and Modification with Cross-linkers
Introduction to Cross-linkers
Cross-linkers are chemical reagents used to conjugate molecules together by the
formation of covalent bond. Different cross-linkers have different functional groups that
allow differential reactivity to specific target moiety. The cross-linkers used in this study
were BS3 (bis(sulfosuccinimidyl) suberate, MW: 572.43, MF: C16H18N2Na2O14S2), DST
(disuccinimidyl tartrate, MW: 344.24, MF: C10H12N2O10), Sulfo-EGS (ethylene
glycolbis(sulfosuccinimidylsuccinate), MW: 660.45, MF: C18H18N2Na2O18S2), BM(PEG)3
(1,11-bis(maleimido)triethylene glycol, MW: 352.34, MF: C16H20N2O7) and EDC (1-ethyl3-(3-dimethylaminopropyl) carbodiimide hydrochloride, MW: 191.7, MF: C8H17N3·HCl)
(Figure 2).
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Figure 2. Chemical structures of cross-linkers used to modify Ara h2.

BS3, DST, and sulfo-EGS all contain N-hydroxysccinimide ester (NHS ester) that
react with nucleophiles to release the NHS or sulfo-NHS leaving group and form an
acylated product with varying spacer arm length (reaction schematic described below).59
NHS ester can react with sulfhydryl or hydroxyl group but the conjugation is not stable and
it can be hydrolyzed in aqueous solutions. Reaction with primary and secondary amines is
however more stable. A 3D molecular modeling of Ara h2 showing lysine residues which
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contain primary amines for reaction can be seen in Figure 3 which was created using VMD
software.26 BM(PEG)3 cross-linker has maleimide group on each side which helps
conjugate between sulfhydryl groups. BM(PEG)3 contains a poly(ethylene glycol) (PEG)
as spacer arms which helps make PEG cross-linker hydrophilic compared to hydrocarbon
spacers. EDC is a carboxyl and amine-reactive zero-length cross-linker that forms amide
bonds. It is named zero-length cross-linker since the bond formed between the conjugates
contain no additional atoms, it is simply a covalent bond between two molecules.60

Figure 3. Molecular modeling of Ara h2 showing Lys residues using VMD software.26
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BS3 is a homobifunctional NHS ester crosslinking reagent that adds an eight-atom
bridge (11.4 Å) between conjugated molecules.61 This reagent is forming irreversible bond
with the protein since the hydrocarbon chain is non-cleavable. The sulfonate groups give a
negative charge to the molecule making it water soluble. NHS esters are reactive towards
primary amino groups (-NH2) in pH 7 to 9 buffers to form stable amide bonds. The
recommended buffers to use are amine free such as Tris, glycine, or imidazole buffers so
that the amines from the buffer do not cross-react with the NHS ester. The NHS ester forms
amide linkages with α-amines and ε-amines of proteins like primary amines on the side
chain of lysine residues and on the N-terminus of each polypeptide making them a good
target by NHS ester reagents.60 A reaction schematic can be seen in Figure 4 involving BS3
cross-linker.

Figure 4. Reaction schematic of cross-linker BS3. An amide bond is formed leading to
conjugation of two molecules. The cross-linker is non-cleavable.
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DST is a homobifunctional NHS ester crosslinking reagent that contains a central
diol that is cleavable by sodium periodate thus making the conjugation reversible.62 The
reagent adds 6.4 Å of space between conjugated molecules. DST is not so soluble in
aqueous buffers thus it needs to be pre-dissolved in organic solvents such as THF, DMF,
or DMSO prior to addition with molecules that need to be conjugated. The recommended
buffer to use are amine free such as Tris, glycine, or imidazole buffers with optimal pH of
7 to 9. As mentioned before, conjugation with this cross-linker can be cleaved using 0.015
M sodium periodate.60 A reaction schematic can be seen in Figure 5 involving DST crosslinker.
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Figure 5. Reaction schematic of cross-linker Sulfo-EGS. An amide bond is formed leading
to conjugation of two molecules. The ester groups are cleavable in basic conditions using
hydroxylamine.

Sulfo-EGS is a homobifunctional crosslinking agent that contains NHS ester groups
on the ends as well. Middle of the reagent is constructed from an ethylene glycol group
esterified on either side with succinic acid. Sulfo-EGS is water soluble due to the negatively
charged sulfonate groups on its NHS rings. This reagent adds a space of 16.1 Å between
the conjugated molecules.59 The NHS esters are reactive towards amines thus an amine
free buffer is recommended with optimum pH range of about 7 to 9 of the buffer. The
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central bridge of EGS provides two cleavable ester sites at pH 8.5 by incubation with 1-M
hydroxylamine for 3 to 6 hours at 37° C.60,63 A reaction schematic can be seen in Figure 6
involving sulfo-EGS cross-linker.
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BM(PEG)3 contains bifunctional thiol reactive maleimides on each end that
produces stable thioether linkages with sulfhydryls.64 The cross-linker is hydrophilic with
spacer arm of 17.8 Å. BM(PEG)3 is recommended in pH range of 6.5 to 7.5 for reaction
towards sulfhydryl groups and pH of >8 for primary amines, however, reaction rate is 1000
times slower with amines. Sodium phosphate (0.01-0.1 M) buffer works well for this
reaction making sure to avoid amine-containing buffers along with sulfhydryl-containing
disulfide reductants such as DTT or 2-mercaptoeathanol. A 3D molecular modeling of Ara
h2 showing disulfide bonds can be seen in Figure 7 that was created using VMD software.26
Maleimide moiety can hydrolysis resulting in opening of the maleimide ring rendering it
nonreactive.60 A reaction schematic can be seen in Figure 8 involving BM(PEG)3 crosslinker.
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Figure 7. Molecular modeling of Ara h2 showing Cys residues using VMD software.26
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Figure 8. Reaction schematic of cross-linker BM(PEG)3. Formation of thioether linkages
on molecules or proteins that contain thiol groups.

EDC is a carbodiimide with a zero-length crosslinking arm that forms an amide or
phosphoramidate linkage between a carboxylate group and an amine or a phosphate and an
amine, respectively. A 3D molecular modeling of Ara h2 showing Asp and Glu residues
can be seen in Figure 9 that was created using VMD software.26 EDC reacts with carboxylic
acid to form an amine-reactive O-acylisourea intermediate that will react with a
nucleophile such as a primary amine to form an amide bond and release an isourea byproduct as seen in Figure 10. Consideration should be given to the intermediate since it is
unstable in aqueous solutions. Oxygen atoms can also act as a nucleophile as in water
molecules thus resulting in activation of EDC and hydrolysis of the activated ester
intermediate, regenerating the carboxylate group and release of an N-substituted urea.65
Buffers such as MES [2-(N-morpholino)ehane sulfonic acid] at 0.1-M works well at acid
pH conjugation, or a phosphate buffer at 0.1-M works for neutral pH conditions.60 Overall,

26

any buffer that does not contain amines or carboxylic groups or other components that may
react with the carbodiimide can be used.

Figure 9. Molecular modeling of Ara h2 showing Asp and Glu residues using VMD
software.26
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Figure 10. Reaction schematic of cross-linker EDC. Amide bond formation using EDC
between carboxylic acid and primary amine.

The carboxylate activation is most efficient at pH 3.5 to 4.5, while amide bond
formation occurs with highest yield at pH 4 to 6 thus a two-step coupling can be used
(Figure 11). Since there are many by-products that can be formed, sulfo-NHS can be used
to increase the solubility and stability of the active intermediate.66 The active ester, Oacylisourea, is slow to react with amines and can hydrolyze in aqueous solution so
introduction of sulfo-NHS to the active intermediate allows sulfo-NHS ester to form. This
sulfo-NHS ester intermediate is more effective at reacting with amine and thus a higher
yield of amide bond formation can be seen.60,67,68
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Figure 11. Two-step coupling reaction schematic of EDC and sulfo-NHS. Efficiency of
reaction with EDC can be increased by introduction of sulfo-NHS and forming a sulfoNHS ester intermediate which is more stable and reactive towards primary amines.

Research Design and Methods
Protein purification method 1. Ara h2 protein was purified according to Sen et
al.20 with few personal modifications. Roasted, unsalted peanut seeds (Arachis hypogaea,
hypogaea hypogaea) were obtained from Good Earth Peanut Co., Skippers, VA, USA.
Peanut seeds were crushed after freezing them with liquid nitrogen using a mortar and
pestle. Crushed peanuts were placed in a cellulose extraction thimble which was placed in
a soxhlet extraction for defatting with three changes of diethyl ether. Defatted peanut seeds
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were dried by spreading them out on a paper towel over night under the hood. The dried
defatted peanut seeds were crushed into a fine powder using mortar and pestle.
Peanut flour was dissolved in TBS buffer (65 mM Tris-HCl, 1 mM EDTA, 1 mM
PMSF, pH 8.3) with 200 mM NaCl at a ratio of 1 gram to 50 mL buffer. The mixture was
sonicated using Sonics Vibra-Cell at 39% power for 10 mins over ice followed by 1 hour
of stirring at room temperature. The dissolved peanut suspension was then followed by
vacuum filtration thru six layers of cheesecloth. The filtered solution was centrifuged
(Sorvall RC 5B PLUS, SS-34 rotor) at 30,000 X g for 30 mins at 4° C. The supernatant
was fractionated using ammonium sulfate precipitate (NH4)2SO4 (MW 132.14) going from
0 to 40% carrying the supernatant and then carrying the pellet in 40% to 70% precipitate.
The ammonium sulfate was added slowly over 30 min period and stirred for total of 1 hour
over ice followed by centrifugation at 30,000 X g for 30 mins (SS-34 rotor).
The pellet was dissolved in 10 mL of TBS buffer without NaCl followed by
sonication for 1 min at 39% power (over ice) and centrifugation (3,000 X g for 15 min) to
remove undissolved particles. The supernatant was dialyzed (SnakeSkin Dialysis Tubing,
7K MWCO) overnight against TBS buffer to remove salts from the mixture. The
supernatant was loaded onto a flex-column 1.5 x 30 cm (Kimble Chase) filled with
approximately 50 mL of Q Sepharose Fast Flow (GE Healthcare) that had been equilibrated
with TBS buffer. After loading the supernatant, 90 mL of TBS buffer with 40 mM NaCl
was used to elute proteins of noninterest. Then a linear gradient of 400 mL using 200 mL
TBS buffer with 40 mM NaCl to 200 mL TBS buffer with 500 mM NaCl was used to elute
protein of interest at a flow rate of 2 mL/min. Fractions were collected for 1 min 15 secs
per tube to give approximately 2.5 mL per tube.
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The fractions were analyzed using coomassie G-250 dye bonding assay for protein
in a clear 96-well plate. Ratio of 50 µL protein sample to 150 µL coomassie dye was used
followed by reading of the plate at 595 nm (Thermo Scientific Multiskan Spectrum).
Positive fractions were analyzed using SDS-PAGE (see below “SDS-PAGE protocol”) for
Ara h2 followed by dialyses (7K MWCO) overnight at 4° C against 25 mM Tris-HCl (pH
7.4) and 3 M NaCl. The dialyzed sample was loaded onto a flex-column 1.5 x 30 cm
(Kimble Chase) filled with approximately 50 mL of Phenyl Sepharose 6 Fast Flow (high
sub) (GE Healthcare) that had been equilibrated with 25 mM Tris-HCl (pH 7.4) with 3 M
NaCl. After loading, a linear gradient of 200 mL using 100 mL of 25 mM Tris-HCl buffer
with 3 M NaCl to 100 mL of 25 mM Tris-HCl buffer with 0 M NaCl was ran at 1.5 mL/min.
Fractions were collected for 1 min 20 secs per tube to give approximately 2.0 mL per tube.
Fractions were analyzed again for Ara h2 using coomassie G-250 dye bonding assay and
SDS-PAGE. Ara h2 containing fractions were pooled and dialyzed (7K MWCO) overnight
at room temperature against 15 mM ammonium bicarbonate (pH 7.0). The dialyzed sample
was lyophilized (FreeZone 2.5 L Benchtop Freezer Dry System, Labconco) and stored at 20° C.
Protein purification method 2. A second, novel method for purifying Ara h2 was
developed to increase yield and efficiency of the purification process. This method of
purification was inspired by Jumnongpon et al.69 as they purified cocoa protein from cocoa
beans. Cocoa beans consist of 52% albumin and 43% globulins and peanut protein Ara h2
is from the albumin family thus it warranted us to utilize this purification method.
Peanuts were defatted and crushed into fine powder as described above in method
1. The peanut proteins were, however extracted using 0.5% SDS-0.05 M phosphate buffer,
31

pH 6.9 instead of TBS buffer. Peanut powder (0.1 g) was weighed into 1.5 mL Eppendorf
tubes and combined with 1 mL of extraction buffer (multiple batches done at once). The
Eppendorf tubes were placed in a water sonication bath (Model 50T, VWR) for 1 hour
changing the water to keep the water temperature constant at room temperature. After 1
hour, the samples were centrifuged (Allegra 21 Centrifuge, Beckman) at 3,000 X g for 10
mins taking the supernatant out. The precipitates were further extracted by adding 1 mL of
extraction reagent buffer to the Eppendorf tubes followed by 1 hour water sonication bath
and centrifugation at 3,000 X g for 10 mins. The supernatant was combined and pellets
discarded.
The supernatant was filtered using a Whatman syringe filter 1.0 µm GF/B w/GMF
and placed in dialysis tubing (7K MWCO) to be dialyzed against 15 mM ammonium
bicarbonate (5 L bucket) with minimum of 6 changes at 4° C. The extract was then
lyophilized and protein powder (0.050 g) dissolved in 10 mL of TBS buffer (65 mM TrisHCl, 1 mM EDTA, 1 mM PMSF, pH 8.3). The solution was then loaded (10 mL) onto a Q
Sepharose Fast Flow (GE Healthcare) column that was packed with approximately 100 mL
of resin in Flex-Column 2.5 x 30 cm (Kimble Chase). The column was washed with 100
mL TBS buffer containing 40 mM NaCl at flow rate of 2 mL/min to elute proteins of
noninterest. Then a linear gradient of 400 mL using 200 mL TBS buffer with 40 mM NaCl
to 200 mL TBS buffer with 500 mM NaCl was used to elute protein of interest at a flow
rate of 2 mL/min. Fractions were collected for 1 min 15 secs per tube to give approximately
2.5 mL per tube.
The fractions were analyzed for protein as described above in Method 1 using
coomassie G-250 dye bonding assay followed by SDS-PAGE gel to identify fractions
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containing Ara h2. Fractions of interest were collected and dialyzed (7K MWCO)
overnight at room temperature against 15 mM ammonium bicarbonate (pH 7.0) followed
by lyophilization. The sample was resuspended in dH2O (Milli-Q ultrapure) and subjected
to centrifugal filters of 30K MWCO to remove proteins greater than or equal to 30 kDa
(Amico Ultra-15, Ultracel-30K, Merck Millipore). The centrifuged protein was verified for
purity by SDS-PAGE, lyophilized and stored at -20° C.
BS3 reaction. Protein powder that had been lyophilized was dissolved in 20 mM
HEPES, pH 8 buffer to give a concentration of 12 mg/mL as confirmed by BSA standard
curve. This dissolved protein was used as a stock to separated and diluted by two-fold to
give two different concentrations, 6 mg/mL and 12 mg/mL. BS3 (Lot #PD198244, prod. #
21580, Thermo Scientific) was dissolved in 20 mM HEPES, pH 8 buffer to obtain
concentrations of 100, 50, 25, and 12.5 mM. These concentrations were created in
duplicates to accompany the two separate protein concentrations. The cross-linker was
prepared immediately before adding to the protein to prevent from hydrolysis of NHS ester.
The dissolved protein and BS3 solution was added at a 1:1 volume ratio (35 µL:35
µL) followed by incubation for 30 mins at room temperature followed by SDS-PAGE
analysis (Figure 12a). After 30 mins of incubation at room temperature, samples were
placed at 37° C for continued reaction with cross-linker followed by SDS-PAGE analysis
after 2 days (Figure 12b) and 6 days (Figure 12c) (Gel from Thermo Scientific, 2x sample
buffer & marker from Novagen). Due to 1:1 ratio, the final protein concentration and BS3
cross-linker concentration was cut in half. This gave final protein concentration of 6
mg/mL from 12 mg/mL and 3 mg/mL from 6 mg/mL. The final concentration of crosslinker was 50, 25, 12.5, and 6.25 mM from initial 100, 50, 25, and 12.5 mM, respectively.
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Another condition of increasing the pH from 8 to 10.7 was tested to see if crosslinking can be enhanced with BS3. Same conditions as above were used, however, only one
protein concentration of 6 mg/mL was tested instead of both. Again, fresh batch of BS3
was prepared at concentrations of 100 mM to 12.5 mM as above. The reaction was
completed in duplicate so that one set can be placed at room temperature and the other in
the incubation at 37° C. The reaction mixture was allowed to incubate followed by SDSPAGE analysis after 1 day (Figure 13a) and 4 days (Figure 13b) (Gel from Thermo
Scientific, 2x sample buffer & marker from Novagen). Same ratio of protein to cross-linker
was used as above at 1:1 volume ratio (35 µL: 35 µL) diluting the protein and cross-linker
concentration by half. This gave final protein concentration of 3 mg/mL from 6 mg/mL
and final concentration of cross-linker of 50, 25, 12.5, and 6.25 mM from initial 100, 50,
25, and 12.5 mM, respectively.
Since the NHS ester is reactive towards sulfhydryl and primary amine groups, a
reducing agent 2-mercapaptoethanol was added to reduce disulfide bonds and open the
structure so that more possible reactive sites can be accessed by BS3. Lyophilized protein
powder was dissolved in 20 mM HEPES, pH 8.0 buffer and separated in duplicates. To
one protein solution, 1.4 µL of 2-mercaptoethanol was added after 15 mins of incubating
the protein at 37° C. Fresh BS3 was prepared immediately before adding to the protein at
concentrations from 35 mM to 65 mM in 5 increments. Protein and cross-linker were added
at 1:1 volume ratio (50 µL:50 µL) followed by incubation at 37° C.
Due to 1:1 ratio, the final protein concentration and BS3 cross-linker concentration
was cut in half. This gave final protein concentration of 2 mg/mL from 4 mg/mL of protein.
The final concentration of cross-linker was 32.5, 30.0, 27.5, 25.0, 22.5, 20.0, and 17.5 mM
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from initial 65, 60, 55, 50, 45, 40, and 35 mM, respectively. Since no reaction was observed
within 30 mins or 2 days of incubation, an SDS-PAGE analysis was performed after 5 days
of incubation (Figure 14) (Gel from Thermo Scientific, 2x sample buffer & marker from
Novagen). Before loading the protein onto the gel, 0.5 µL of 1 M glycine was added to 10
µL of protein and cross-linker solution to quench any unreacted cross-linkers in the
solution. Then 10 µL of 2x Laemmli sample buffer was added to the quenched solution
which turned green/yellow due to pH change. Thus, to bring the solution back to blue, 1
µL of 1 M NaOH was added to the solution.
Sulfo-EGS reaction. Protein powder that had been lyophilized was dissolved in 20
mM HEPES, pH 8 buffer and 20 mM HEPES, pH 10.7 buffer to give concentrations of 8.6
mg/mL and 11.6 mg/mL, respectively, as confirmed by BSA standard curve. Sulfo-EGS
(Lot #CK2606, prod. #C1129, ProteoChem) was dissolved in 20 mM HEPES, pH 8 buffer
and 20 mM HEPES, pH 10.7 buffer to obtain concentrations of 10, 5, 2.5, and 1.25 mM.
These concentrations were created in four sets to accompany the two-different pH and two
different temperature conditions. The cross-linker was prepared immediately before adding
to the protein to prevent hydrolyzes of NHS ester.
The dissolved protein and Sulfo-EGS solution was added at a 1:1 volume ratio (37.5
µL:37.5 µL). Due to 1:1 ratio, the final protein concentration and Sulfo-EGS cross-linker
concentration was cut in half. This gave final protein concentration of 4.3 mg/mL from 8.6
mg/mL and 5.8 mg/mL from 11.6 mg/mL. The final concentration of cross-linker was 5,
2.5, 1.25, and 0.625 mM from initial 10, 5, 2.5 and 1.25 mM, respectively. One sample
with buffer at pH 8 was incubated at room temperature (Figure 15a) and another at 37° C
(Figure 15b). Same was done for reaction mixture with buffer at pH 10.7, one at room
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temperature (Figure 15c) and another at 36° C (Figure 15d). An SDS-PAGE analysis was
done 54 days after due to insufficiency of SDS-PAGE gels at the time (Gel from Thermo
Scientific, 2x sample buffer & marker from Novagen).
DST reaction. Protein powder that had been lyophilized was dissolved in 20 mM
HEPES, pH 10.7 buffer to give concentration of 4 mg/mL, as confirmed by BSA standard
curve. Since the NHS ester is reactive towards sulfhydryl and primary amine groups, a
reducing agent 2-mercapaptoethanol was added. The protein was split with one having 2mercaptoethanol (added after incubating protein at 37° C for 15 mins) and one without.
DST (Lot #DD2687, prod. #C1133, ProteoChem) was dissolved in 20 mM HEPES, pH
10.7 buffer. DST is not soluble in HEPES buffer so DMSO (7% final concentration) was
used to dissolve the cross-linker. The same amount of DMSO was also added to the control
protein.
A serial dilution was carried out from 25 mM to 3.125 mM with 4 total
concentrations. The dissolved protein and DST solution was added at a 1:1 volume ratio
(50 µL:50 µL). Due to 1:1 ratio, the final protein concentration and Sulfo-EGS cross-linker
concentration was cut in half. This gave final protein concentration of 2 mg/mL from 4
mg/mL. The final concentration of cross-linker was 12.5, 6.5, 3.1, and 1.6 mM from 25,
12.5, 6.3, and 3.1 mM, respectively. Protein was incubated at 37° C followed by SDSPAGE analysis 2 days later (Figure 16) (Gel from Thermo Scientific, 2x sample buffer &
marker from Novagen). Before running the gel, 0.5 µL of 1 M glycine was added to quench
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any unreacted cross-linkers in the solution followed by 2x Laemmli sample buffer and 1
µL of 1 M NaOH to turn the solution back to blue from the pH change.
BM(PEG)3 reaction. Protein powder was dissolved in 20 mM HEPES, pH 8 to
give a concentration of 4 mg/mL as confirmed by BSA standard curve. Since BM(PEG)3
is a cross-linker that conjugates between sulfhydryl groups, the protein had to be reduced
and this was carried out by using immobilized TCEP disulfide reducing gel (Thermo
Scientific). To test the reducing activity of TCEP, Ellman’s reagent was used which did
confirm the gel was active after color change to yellow. The dissolved protein was added
to TCEP resin that was equilibrated with 20 mM HEPES, 20 mM EDTA, pH 8 by vortexing
for 1 min followed by centrifuge at 1,000 X g and removing supernatant. The protein (250
µL) and resin (500 µL) mixture was mixed in an Eppendorf tube and stirred for 2 hours at
room temperature followed by centrifuge at 1,000 X g for 1 min, carrying the supernatant.
Another 100 µL of buffer was added to the Eppendorf tube to extract any remaining protein
from the resin mixture.
BM(PEG)3 (Lot # RA230660, Prod # 22337, Thermo Scientific) was dissolved in
DMSO (13.3%) followed by serial dilution to obtain following concentrations: 153.26,
76.63, 38.32, 19.16, 9.58, 4.79, 2.39, 1.20, 0.60, and 0.30 mM. Cross-linker was prepared
and covered in foil to protect from light immediately before adding to already reduced
protein. Added 130 µL of reduced protein and 20 µL of cross-linker at varying
concentrations. Samples were incubated at room temperature followed with SDS-PAGE
analysis after day 1 (Figure 17a) and day 7 (Figure 17b). (Gel from Bio-Rad, 5x sample
buffer & marker from Bio-Rad). Final protein concentration was 3.5 mg/mL and final
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cross-linker concentrations were: 20.43, 10.22, 5.11, 2.55, 1.28, 0.639, 0.319, 0.160,
0.0798 and 0.0399 mM.
EDC reaction. In order to modify/mask IgE binding epitopes of Ara h2, a peptide
called TV1 (sequence: MDAEFRHDS-NH2, MW: 1107.2) was reacted in the presence of
EDC. This was carried out in order to crosslink with one of the amino acids on the epitopes
or at least mask the epitope sites with the peptide. Protein was reacted with cross-linker
EDC and sulfo-NHS via 2-step reaction since it is more efficient as described above. Since
Ara h2 has high percentage of glutamic acid and aspartic residues, it was used in the
activation reaction with EDC. The activation buffer is recommended to have pH between
4.5-7.2 (without amines or carboxylate in the buffer) so 4-Morpholineethanesulfonic acid
(MES) was used. Activation buffer consisted of 0.1 M MES, 0.5 M NaCl, pH 5.0 that was
used to dissolve the protein for a protein concentration of 8.0 mg/mL as confirmed by a
BSA standard curve.
Since coupling buffer is recommended to be at pH 7-8, a phosphate-buffered saline
(PBS) was used (100 mM sodium phosphate, 150 mM NaCl, pH 7.2). The TV1 peptide
was dissolved in PBS buffer to give a concentration of 1.5 mM. EDC was equilibrated to
room temperature before opening. To the activated protein in MES buffer, 2 mM of EDC
and 5 mM of sulfo-NHS was added and allowed to react for 15 mins at room temperature.
The reaction was quenched of unused EDC by adding 2-mercaptoethanol at a final
concentration of 20 mM. Peptide containing solution was added to the quenched activated
protein solution and allowed to react for 2 hours at room temperature. Final concentration
of protein was 4 mg/mL since 1:1 volume ratio of Protein and TV1 peptide was used. The
whole reaction was quenched by adding hydroxylamine at final concentration of 10 mM
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which hydrolyzes nonreacted NHS present on the protein and results in hydroxamate. An
SDS-PAGE analysis (Figure 18) was done after quenching the reaction using gel from
Thermo Scientific, 2x sample buffer & marker from Novagen.
SDS-PAGE protocol. Two different brands of sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gels were used, however, both contained
the same polyacrylamide gradient of 4% to 20%. A 4-20% Mini-PROTEAN TGX (TrisGlycine eXtended) Precast Protein Gels, 12-well, 20 µL from Bio-Rad and another a 420% Precise Tris-Glycine Precast Gels, 12-well, 20 µL from Thermo Scientific. A 2x
Laemmli sample buffer or 5x Laemmli sample buffer was used that was made according
to Cold Spring Harbor Protocols (120 mM Tris-Cl, 4% SDS, 20% v/v glycerol, 0.2 M DTT,
0.02% w/v bromophenol blue, pH 6.8). Two different protein markers were used for
reference on the SDS-PAGE gels. Commercially available Protein Marker, (Novagen) with
molecular weights of 15, 25, 35, 50, 75, 100 and 150 kDa was used when gel from Thermo
Scientific was run or Precision Plus Protein Standards Dual Color (Bio-Rad) with
molecular weights of 10, 15, 20, 25, 37, 50, 75, 100, 150 and 250 kDa was used when gel
from Bio-Rad was used. Gel was running at 110 V until the dye front reached the bottom
of the gel. Gel was stained with staining solution created with Coomassie brilliant blue R250 followed by de-staining until bands were visible. Gel was imaged using Azure
Biosystems c300.
Results and Discussion
NHS ester reactions. BS3 reaction without any addition of 2-mercaptoethanol was
tested to see if protein can be modified without reduction. The protein used for this batch
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was not pure with just Ara h2 as it has other proteins as seen in Figure 12(a, b, c), lanes 2
& 8 (control lanes) for concentrations of 12 mg/mL and 6 mg/L, respectively. The purpose
of this reaction was a prove of concept to see if any cross-linked dimer or oligomers are
observed with BS3 cross-linker. As seen by the SDS-PAGE gel in Figure 12(a, b, c) that
there was disappearance of Ara h1 as the concentration of cross-linker was increased from
left to right. This is possibly proving that Ara h1 was cross-linked and due to high MW, it
could have precipitated out of solution without being loaded onto the gel.
Protein Ara h2 after 30 mins of incubation at room temperature Figure 12(a) with
BS3 appears to have little effect as noted by the same density of the protein bands as
concentration of cross-linker is increased from left to right on the SDS-PAGE. There is
slight decrease in intensity of Isoform Ara h2.02 in Figure 12(a), lane 12 which could
possibly have cross-linked and precipitated out of solution. However, after placing this
same protein/cross-linker mixture at 37° C followed by SDS-PAGE analysis 2 days (Figure
12(b)) and 6 days (Figure 12(c)) after showed Ara h2.01 and Ara h2.02 band intensity
decrease, almost nothing to very faint. This was only observed at the highest cross-linker
concentration of 50 mM BS3 (Figure 12(b, c) lanes 6 & 12). There are two possible reasons
that Ara h2 band intensity decreases with no possible dimerization or multimerization. One
reason is that the protein could have cross-linked with decreased solubility causing the
protein to precipitate out of the solution. The other reason is that the high concentration of
BS3 could have some effect on the SDS-PAGE gel.
BS3 was tested with different pH as well to see if that would promote cross-linking
among peanut proteins thus pH was changed from 8 to 10.7. Protein and cross-linker were
incubated for 1 day (Figure 13(a)) and 4 days (Figure 13(b)) followed by SDS-PAGE
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analysis. Batch was split in half with one at room temperature and other at 37° C. It can be
seen that as concentration of BS3 is increased from left to right, there is a decrease in protein
band intensity of Ara h2, Ara h1 and Ara h3. As for the highest concentration of BS3 there
is a disappearance of all the proteins from that lane as compared to the control lane. This
could be due to the protein being cross-linked and precipitating out of the solution or it
could be that particular concentration of BS3 could be have a reaction with the SDS-PAGE
gel, however, this is undetermined and an area for future investigation.
Since BS3 reaction without 2-mercaptoethanol showed little evidence of
dimerization or oligomerization, another set of reactions were set up that included the
reducing agent 2-mercaptoethanol. Since this batch of protein was different, both nonreducing and reducing conditions were used. It can be seen from Figure 14(a) and 14(b)
that there is no dimer or oligomers observed on the SDS-PAGE gel. What can be noticed
is that the decrease in intensity of protein is observed compared to the control. This is
observed in both the reducing and non-reducing conditions of the protein. This means that
it must be BS3 interfering with the SDS-PAGE gel and causing the band intensity to
decrease and not the reducing agent. There is a decrease in Ara h1 as noticed with protein
band disappearance. Thus, it is highly likely that BS3 has reactivity towards Ara h1 and
possibly some reactivity towards Ara h2 at 50 mM BS3 concentration. Since Ara h1 is also
a major peanut allergen, this can be of a further study by isolating and reacting Ara h1 with
cross-linker. Further testing is required to confirm if Ara h2 concentration has decreased
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due to modification or cross-linker by testing patient’s IgE reactivity to the modified
protein in an ELISA or Western Blot assay.
Protein reaction with Sulfo-EGS cross-linker showed no new formation of dimer
or oligomer (Figure 15). The SDS-PAGE gels from Figure 15(a, b, & c) show no reactivity
as the band intensity of Ara h2 protein (or any other protein on the gel) have not decreased
along with no new bands as compared to the control. Even trying two different pH (8 &
10.7) and two different temperature (room temperature & 37° `C) showed no sign of crosslinking. Gel from Figure 15(d) (lane 6) shows possible crosslinking with new bands
appearing between 60-70 kDa as compared to the control. Lane 7 which is the next higher
concentration of cross-linker shows decrease in Ara h2.02 band however no new band
formation to indicate cross-linking. Upon repeating the SDS-PAGE (data not shown) with
same condition, there was no evidence of those bands, which indicate that those bands
between 60-70 kDa were from some other impurities. It could be possible that upon
repeating the SDS-PAGE gel, the cross-linked protein might have precipitated out and was
not being loaded into the well.
DST cross-linker was applied which was dissolved in 7% DMSO. This same
percentage of DMSO was also added to the control Ara h2 protein as well. DST was reacted
with Ara h2 for 2 days (Figure 16) followed by SDS-PAGE gel to observe for cross-linking
between protein. Protein was split into duplicate with one set having 2-mercaptoeathanol
and the other without it. As seen on the gel, there is no new formation of dimer or oligomer.
What can be seen is in lanes 5 & 10 a decrease in band intensity of Ara h2 which is at the
highest concentration of DST used (12.5 mM). This can be due to two reasons; if Ara h2
did cross-link, it could have precipitated out or DST itself at that concentration could be
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interacting with the SDS-PAGE gel. Again, this has to be further tested by using IgE from
patient allergic to peanut in an ELISA and Western Blot assays to see if the reactivity is
the same.
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(a)

(b)

(c)
Figure 12. SDS-PAGE of BS3 cross-linker in pH 8. SDS-PAGE after 30 mins (a) of
reaction with BS3 in 20 mM HEPES, pH 8 at room temp. SDS-PAGE after 2 days (b) of
reaction with BS3 in 20 mM HEPES, pH 8 at 37°C. SDS-PAGE after 6 days (c) of reaction
with BS3 in 20 mM HEPES, pH 8 at 37°C. Lanes: (1 & 7) molecular marker (2 & 8) control
(3 to 6 & 9 to 12) 6.25 mM to 50 mM of BS3 left to right. Concentration of protein in lanes
(2 to 6) is 6 mg/mL and (8 to 12) is 3 mg/mL.
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(a)

(b)

Figure 13. SDS-PAGE of BS3 cross-linker in pH 10.7. SDS-PAGE after 1 day (a) and 4
days (b) of reaction with BS3 in 20 mM HEPES, pH 10.7 at room temp and 37°C. Lanes:
(1 & 7) molecular marker (2 & 8) control (3 to 6 & 9 to 12) 6.25 mM to 50 mM of BS3 left
to right. Lanes (2 to 6) are samples incubated at 37°C and (8 to 12) are samples incubated
at room temp. Final concentration of protein at 3 mg/mL.
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(a)

(b)

Figure 14. SDS-PAGE of BS3 cross-linker in pH 8 with and without 2-mercaptoethanol.
SDS-PAGE after 5 days of reaction with BS3 in 20 mM HEPES, pH 8 at 37°C. (a) Protein
plus BS3 without 2-mercaptopethanol (b) Protein plus BS3 plus 2-mercaptoethanol. Lanes:
(a)(1) molecular marker (2) control without 2-mercaptoethanol and (3 to 9) 17.5 mM to
32.5 mM in 5 increments. (b)(1) molecular marker (2) control without 2-mercaptoethanol
(3) control with 2-mercaptoethanol (4 to 10) 17.5 mM to 32.5 mM left to right. Final
concentration of protein at 2 mg/mL.
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(a)

(b)

(c)

(d)

Figure 15. SDS-PAGE of Sulfo-EGS cross-linker. SDS-PAGE after 54 days of reaction
with Sulfo-EGS in 20 mM HEPES, pH 8 and pH 10.7 at room temp and 37°C. (a) pH 8
at room temp. (b) pH 8 at 37°C (c) pH 10.7 at room temp. (d) pH 10.7 at 37°C. Lanes:
(1a,b,c,d) molecular marker (2a,b,c,d) control (3 to 7) 0.625 mM to 5 mM of Sulfo-EGS
left to right. Final concentration of protein (a,b) is 4.3 mg/mL and (c,d) is 5.8 mg/mL.
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Figure 16. SDS-PAGE of DST cross-linker. SDS-PAGE after 2 days of reaction with DST
in 20 mM HEPES, pH 10.7 at 37°C. Lanes: (1) control with 2-mercaptoethanol (6) control
without 2-mercaptopethanol (11) molecular marker ((2 to 5) with 2-mercaptoethanol & (7
to 10) without 2-mercaptoethanol) 1.6 mM to 12.5 mM of DST left to right. Final
concentration of protein at 2 mg/mL.

Sulfhydryl reaction using maleimide. BM(PEG)3 was reacted with Ara h2 protein
for 1 day (Figure 17(a)) and 7 days (Figure 17(b) followed by SDS-PAGE analysis. As
seen by the SDS-PAGE gel after 1 day and 7 days of incubation, there is no formation of
dimer or oligomer. As a reminder, no reducing agent was added to this batch since TCEP
resin was used to reduce protein before addition of cross-linker. There is a possibility that
the cross-linker might have attached to one or more sulfhydryl groups of cysteine residues
but not cross-linked with another protein which could be due to steric hindrance. The cross48

linker could have been inserted between the sulfhydryl groups but since the cross-linkers
are of small molecular weight, they are not seen by SDS-PAGE analysis.

(a)

(b)
Figure 17. SDS-PAGE of BM(PEG)3 cross-linker. SDS-PAGE after 1 day (a) and 7 days
(b) of reaction with BM(PEG)3 in 20 mM HEPES, pH 8 at room temp. Lanes: (1)
molecular marker (2) control (3 to 12) 0.0399 mM to 20.43 mM of BM(PEG)3 from left to
right. Final concentration of protein at 3.5 mg/mL.
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Amide bond formation between carboxylic acid and primary amine. EDC was
used to try and conjugate Ara h2 with TV1 peptide using 2 step conjugation reaction with
sulfo-NHS. As seen by SDS-PAGE in Figure 18 that there is no dimer or oligomerization
observed. There are multiple possibilities why this is observed. Since the peptide is small
with low molecular weight, it possibly could have attached itself to the protein but just not
displayed on the SDS-PAGE gel.

Figure 18. SDS-PAGE of EDC cross-linker. SDS-PAGE of reaction of Ara h2 with TV1
peptide using cross-linker EDC with sulfo-NHS in a 2-step reaction. Lanes: (1) control
(2) EDC + TV1 peptide (3) molecular marker. Final concentration of protein at 4 mg/mL.
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One test that can be employed on all the cross-linker is to do mass spectroscopy to
see if the weight of the protein changed before and after addition of cross-linker. Another
test can be tried to validate for the secondary structure of protein by using Circular
Dichroism spectroscopy. Again, all these cross-linker could have attached to the protein
and disrupted molecular binding between the proteins without actually conjugating with
another protein but due to low molecular weight of cross-linker, they are not detectable by
SDS-PAGE analysis. Thus, to really confirm a change in protein structure or addition of
one or two cross-linkers without conjugation to another protein, an ELISA or Western Blot
analysis can be carried out with IgE from patient serum that are allergic to peanut allergy.
Method 1 vs method 2. Most important part of cross-linking Ara h2 was to purify
Ara h2 from peanuts at a continuous and efficient way so other parts of the research are not
hindered. Basically, purification of protein from peanut seeds was the rate determining step
in this study. The procedure that was used to in the beginning of this study was method 1.
This procedure involved 2 different chromatography columns with multiple steps utilizing
many resources and time. Thus, method 2 was derived which involved only one
chromatography column with fewer steps involving fewer resources and saving time.
Both method 1 and method 2 begins by defatting crushed peanut seeds using
Soxhlet extraction in ether solvent. The next step was dissolving this defatted peanut
powder in buffer and this is where the two methods make their first split. Method 1 used
TBS buffer and Method 2 used phosphate buffer with 0.5% SDS. Method 2 originally used
two different buffers to extract proteins: 0.5% SDS + 0.02 M phosphate buffer, pH 6.9
(“0.5% SDS” buffer hereafter) and 8 M Urea + 1% 2-mercaptoethanol (“8 M Urea”
hereafter). Both buffers showed different proteins that were extracted as seen by SDS51

PAGE (Figure 19). Lane 2 & 3 contain protein that had been extracted, dialyzed (overnight
against dH2O), and lyophilized using 8 M Urea and 0.5% SDS, respectively. Protein
powder extracted using 8 M Urea (0.0038 g) and 0.5% SDS (0.0037 g) was dissolved in 1
mL of 20 mM HEPES, pH 8. Lanes 4 & 5, 8 M Urea and 0.5% SDS, respectively, were
proteins loaded with the extraction buffer. It can be seen that extraction with 0.5% SDS
buffer showed Ara h2 being extracted with very few other protein as compared to extraction
with 8 M Urea buffer. Thus, 0.5% SDS buffer was used for method 2 instead of 8 M Urea.

Figure 19. SDS-PAGE analysis of different buffers used to extract protein. Lanes: (1)
molecular marker (2) 8 M Urea (dialyzed, lyophilized, and re-dissolved protein powder)
(3) 0.5% SDS (dialyzed, lyophilized, and re-dissolved protein powder) (4) protein in 8 M
Urea buffer (5) protein in 0.5% SDS buffer.
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In comparison, Method 1 protein extract was filtered using cheese cloth followed
by ammonium sulfate precipitate twice, first going from 0 to 40% carrying the supernatant
and then carrying the pellet in 40% to 70%. This part of the procedure was omitted in
Method 2. Instead, the protein with extraction buffer was just subjected to centrifuge
carrying the supernatant and passing it through syringe filter instead of cheese cloth. Next
step in Method 1 requires dialyzing the pellet against TBS buffer so that it can be loaded
onto Q Sepharose column. Method 2 also took the protein extract and was subjected to
dialysis against 15 mM ammonium bicarbonate buffer. Protein from Method 1 was loaded
onto the column after dialysis whereas protein that was on the lyophilizer was dissolved in
TBS buffer and then loaded onto the Q Sepharose column.
After loading protein onto the column, both were subjected to running gradient of
TBS buffer containing 40 mM to 500 mM NaCl after 100 mL of TBS buffer with 40 mM
NaCl was ran through to elute protein. Method 1 requires fractions that contain Ara h2 to
be dialyzed against Tris buffer containing 3 M NaCl and then loaded onto a phenyl
sepharose column for another column chromatography. Method 2 takes proteins that
contain Ara h2 after doing coomassie G-250 dye bonding assay to find those fractions as
seen in Figure 20 that shows which fractions were collected followed by SDS-PAGE
analysis (Figure 21). It can be seen that Ara h2 (Figure 12, lane 4) along with other lower
molecular weight proteins elute out of Q Sepharose column earlier followed by heavier
proteins like Ara h1 (Figure 21, lane 11). The fractions containing Ara h2 are then subjected
to centrifugal filter of 30K MWCO to eliminated proteins above 30K and thus purifying
Ara h2. It can be noted that Method 2 can also be used to purify Ara h1 as well if needed.
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A summary of the two-different methods is presented in a flowchart analysis in Figure 22
along with the amount of time needed to complete each step.
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Figure 20. Analysis of fractions at absorbance 595 after Q-Sepharose column chromatography. Lanes of SDS-PAGE are labeled
corresponding to the fractions that were collected and loaded onto the following lane well. SDS-PAGE (Figure 21).

Figure 21. SDS-PAGE of fractions collected after Q-Sepharose column chromatography
using Method 2. Fractions are labeled under the lanes. Lane (7) molecular marker.
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Figure 22. Flowchart comparison of Method 1 and Method 2.
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Conclusion
Overall, the reaction of cross-linkers with Ara h2 was negative to visualize a dimer
or oligomer formation on SDS-PAGE; however, a new purification method was developed
that requires less steps and time to purify Ara h2 and Ara h1. Cross-linkers containing NHS
esters could have reacted with Ara h2 protein; however, further characterization of crosslinked product is needed to confirm. What was observed was that at higher concentration
of cross-linkers like BS3 there was precipitation of protein out of the solution. This was
seen for both Ara h2 and Ara h1 along with other proteins. The precipitation can be
confirmed since the protein band intensity decreased as concentration of cross-linker was
increased. Reaction with bifunctional thiol reactive maleimides was inconclusive
according to SDS-PAGE gel. Reaction with EDC cross-linker was not visualized as well
on the SDS-PAGE requiring further characterization. EDC reacts with a carboxylic acid
group, which Ara h2 has plenty of as seen in Figure 9. The peptide that was used, TV1,
could possibly be attached on Ara h2. As mentioned before, the proteins could have one of
the cross-linkers attached without being visualized on the SDS-PAGE and that further tests
are required to characterize the structures of protein comparing before and after addition
of cross-linker.
One of the possibility of not seeing cross-linking among Ara h2 protein could be
the use of roasted peanuts. As stated in the introduction, roasted peanuts are subjective to
the Maillard reaction which modifies lysine and arginine residues via glycosylation bond
with sugars. Since Ara h2 protein was extracted from roasted peanut (most amount of
protein extractable compared to raw protein), it is a possibility that Ara h2’s lysine sites
could be glycosylated making them unreactive towards NHS esters. Since there are only
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3 lysine in Ara h2 (Figure 3), the reaction could be very slow requiring very precise energy
and collision with cross-linker in the solution. Use of raw peanuts is a possibility in
modifying Ara h2 since those proteins will not be glycosylated.
If the cross-linkers were to have reacted with Ara h2, there would have been a dimer
or trimer formation seen on the SDS-PAGE. This dimer or trimer would have been isolated
and characterized followed by purification of the allergoid. The allergoid would then have
been sent out for in vivo testing to see if it has an effect on allergenicity in animals allergic
to peanuts. If the in vivo study would have been followed, the allergoid would have
proceeded to further studies and possibly as a modified allergen for use in EPIT studies on
human.
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Chapter 3
Dipeptidyl Peptidase-IV Inhibition for Treatment of Type 2 Diabetes
Introduction
Diabetes mellitus. Undoubtedly diabetes is one of the most severe disease in the
human history. Diabetes has been found dating back around 1500 B.C. by the ancient
Egyptians, who found effected people to urinate frequently and lose weight. The term
diabetes mellitus was first coined by Greek physician Aretaeus who lived from about 80 to
138 C.E. Since the first measurements of glucose in urine in 1776 till now, there have been
major improvements in understanding and controlling diabetes.70 Diabetes mellitus is a
disease where the blood glucose or blood sugar levels are too high. The homeostasis of
glucose is disrupted because the body is not producing sufficient amounts of insulin or
cannot properly use insulin. Glucose from the food is important to be transported from the
blood to the inside of the cells to produce ATP. This is assisted by the hormone insulin
which is produced by the organ pancreas. There are two types of diabetes mellitus; type 1
diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), both based on the amount
of insulin produced by a person. With T1DM, body does not make insulin and with T2DM,
which is the more common type of diabetes, the body does not make or use insulin well
enough.
T2DM is one of the most important diseases of our time, with reported incidence
increasing yearly among global population dramatically. It is projected that by 2025 there
will be a 13.2 million increase in the number of people suffering from the disease
specifically in the U.S.; with T2DM being the most prevalent and commonly seen in 90-
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95% of the cases. This disease represents to be a global epidemic problem increasing
morbidity, mortality and cost of care as diabetes has also been strongly associated with
cardiovascular and cerebrovascular diseases. Initially at an earlier stage slow advancing
insulin resistance is seen, which later advances to glucose intolerance and finally T2DM
occurs over several years.71
According to the American Diabetes Association, 29.1 million Americans (9.3% of
population) had diabetes in 2012 with 21.0 million diagnosed and 18.8 million
undiagnosed. This is an increase of 1.0% from 25.8 million in 2010 to 29.1 million in 2012.
The incidence of new diabetes cases was about the same in 2012 from 1.9 million in 2010
to 1.7 million in 2012. However, the number of Americans age 20 and older with
prediabetes went up from 79 million in 2010 to 86 million in 2012. Diabetes is also high
in certain ethnicity as 7.6% are non-Hispanic whites, 9.0% Asian Americans, 12.8%
Hispanics, 13.2% non-Hispanic blacks and 15.9% American Indians/Alaskan Natives. The
breakdown among Asian American is as follows; 4.4% Chinese, 11.3% Filipinos, 13.0%
for Asian Indians and 8.8% for other Asian Americans. The breakdown among Hispanic
adults is 8.5% Central and South Americans, 9.3% Cubans, 13.9% Mexican Americans
and 14.8% Puerto Ricans.72
Diabetes is ranked number 7th as the leading cause of death in the U.S. in 2010,
with 69,071 death certificates listing it as the underlying cause of death, and a total of
234,051 death certificates listing diabetes as an underlying or contributing cause of death.
It is mentioned that deaths by diabetes is underreported due to the fact that only 35% to
40% of people with diabetes had it listed on their death certificate as the cause of death and
that about 10% to 15% had it listed as the underlying cause of death.72
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There are also two other categories called prediabetes and gestational diabetes.
Prediabetes just means that you are at a borderline for T2DM and this can be prevented
with proper exercise and diet. Gestational diabetes is when the blood sugar levels are high
during pregnancy. About 7 out of 100 pregnant women in the U.S. get gestational diabetes
and this is when a woman is pregnant for the first time. This increases the chances of
developing T2DM later on and also increases in the child for obesity and T2DM. However,
the focus of this study was on the control of T2DM since it is the most occurring type of
diabetes. A simple blood test can show if you have diabetes which will be explained later
on. Without enough insulin, the glucose from the food stays in the blood and over time can
cause serious problems described hereafter.
Important hormones of pancreas in maintaining homeostasis of blood glucose.
Before dwelling in the symptoms of diabetes, it’s important to know the functions of
pancreas and its secretion of important hormones for the homeostasis of glucose in the
body. The pancreas secretes two important hormones, insulin and glucagon, along with
digestive functions. There are other hormones secreted by the pancreas like amylin,
somatostatin, and pancreatic polypeptide, however, their functions are not well known. The
pancreas is composed of two major types of tissues; the acini and islets of Langerhans. The
acini secrete digestive juices into the duodenum and the islets of Langerhans secrete insulin
and glucagon directly into the blood. Insulin is released from the beta cells which make up
the majority of cells (60% to 70%) in islets of Langerhans and glucagon is released from
alpha cells which make up the second most abundant (25%) of islets of Langerhans.73
Insulin is stimulated by many stimuli with glucose being one of them. Glucose
enters the beta cells via the glucose transporter type 2 (GLUT-2) and it is phosphorylated
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by the enzyme glucokinase which serves as the glucose sensor for the beta cells and triggers
the release of insulin as the glucose exceeds about 5 mM concentration. Another important
factor according to Tan74 is that orally administered glucose causes a greater increase in
insulin than when it is administered via intravenous. The reason for this difference is due
to increased production of incretin hormones such as glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide also called gastric inhibitory polypeptide
(GIP) (discussed in greater detail below). These hormones are secreted by the
gastrointestinal tract when food or glucose is orally consumed and causes direct activation
of G-protein coupled receptors expressed on islet beta cells and thus indirectly increases
insulin production. This is one of the ways to control insulin production and in turn
controlling blood glucose levels.74,75
Insulin is a polypeptide made of two peptide chains, A and B, linked together by
disulfide bridges. It is synthesized as preproinsulin, which is then cleaved in the
endoplasmic reticulum to form proinsulin, which is then self-cleaved in the Golgi apparatus
to form insulin and C-peptide. Insulin causes the storage of excess nutrients while
inhibiting mobilization of endogenous substrates like glycogen. Insulin mediates glucose
entry into most cells, in particular the muscle (skeletal and cardiac) cells. The brain and red
blood cells are exceptions in which glucose is imported via diffusion down a steep
concentration gradient. Insulin also stimulates glycogen production from glucose in muscle
and liver while inhibiting glycogen breakdown in the liver. In adipose tissues, insulin
inhibits triglycerides from breaking down by suppressing hormone-sensitive lipase
activity. This decrease in free fatty acid release from adipose tissues causes a decrease in
beta oxidation by the liver and thus a decrease in the production of ketone bodies. It is also
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commonly seen in patients having T1DM who produce no insulin where the ketone bodies
are increased because free fatty acid release is increased causing diabetic ketoacidosis.74
The other hormone released by the pancreas is Glucagon, which is a 29-amino acid
long peptide produced from proglucagon. Glucagon has almost opposite affect than insulin
in a sense that when blood glucose levels fall, glucagon helps to increase the blood glucose
concentration by converting stored glycogen via glycogenolysis in the liver to glucose.
Glucagon binds to the hepatic membrane receptor and causes a cascade of intracellular
events via cyclic adenosine monophosphate (cAMP) as a second messenger, to regulate
number of enzyme kinases or phosphatases. It is also important to note that patients with
liver disease are hard to treat for hypoglycemia with glucagon. Another function of
glucagon is the activation of myocardial adenylate cyclase which causes an increase in the
cardiac output and should be monitored in T1DM.74
The cascade of insulin resolved glucose clearing from the blood to the tissues is
known as the insulin signal transduction pathway. The activation of insulin receptors by
insulin causes phosphorylation events of many, if not all, downstream components. The
insulin-stimulated phosphorylation of phosphatidyl inositol-3-kinase (PI3K) stimulates the
phosphorylation of two downstream proteins—protein kinase C (PKC)-ζ and protein
kinase B (Akt). Phosphorylated PKC-ζ and Akt initiate two separate pathway branches,
both of which ultimately lead to the translocation of glucose transporter 4 (GLUT4) from
the cytoplasm to the plasma membrane. Once at the plasma membrane, GLUT4 facilitates
the uptake of glucose into skeletal muscle and adipose cells causing a decrease in the blood
glucose levels.76
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Importance of controlling symptoms related to diabetes mellitus. Diabetes is
known to cause number of complications like hypoglycemia, hypertension, dyslipidemia,
stroke, blindness/eye problems, kidney disease and amputations. The common symptoms
of diabetes are polyuria, polydipsia, feeling very hungry even after having a meal, extreme
fatigue, blurry vision, cuts and bruises that are slow to heal, weight loss even though you
are eating more (T1DM) and tingling, pain, or numbness in the hands or feet (T2DM).
These symptoms are easy to detect in T1DM but are so faint in T2DM that they are
sometimes unnoticed. Thus, it is important to detect early and treat diabetes which can
decrease the risk of developing the complications of diabetes. There are several ways to
diagnose diabetes which should be done in a health care setting such as doctor’s office or
at a certified lab that measures blood glucose levels.
In 2011, about 282,000 patients who visited the emergency room and were adults
aged 18 and older had hypoglycemia as the first-listed diagnosis and diabetes as another
diagnosis.72 Hypoglycemia is a condition that is caused by a decrease in blood glucose
levels of less than 70 mg/dL (normal <140 mg/dL). Some of the signs and symptoms of
hypoglycemia include huger, nervousness, shakiness, perspiration, dizziness or lightheadedness, sleepiness and confusion. Hypoglycemia can be grouped into two broad
categories; autonomic and neuroglycopenic. Autonomic consists of sweating, heart
palpitations, shaking, dizziness, hunger, etc. and neuroglycopenic includes confusion,
drowsiness, speech difficulty, odd behavior, incoordination, etc.77
People with chronic kidney disease have a higher frequency of hypoglycemia than
people with diabetes who do not have chronic kidney disease. Chronic kidney diseases
affect how the drug is cleared and thus the drug’s half-life. It also decreases degradation of
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insulin in peripheral tissues resulting in a lowered insulin requirements and thus having
longer lasting effects of insulin in the body. As the body gets older, the kidney functions
decrease and it can be concluded that elderly patients are at increased risk of hypoglycemia.
Their kidneys are insufficient at drug clearance thus increasing drug interactions due to
long lasting effect of drug in the body and decreased cognitive functioning. This leads to
very important concern in elderly patient since hypoglycemia unawareness and
deteriorated cognitive function are critical factors to be carefully considered in treating
older patients.77
In 2011, diabetes was listed as the primary cause of kidney failure in 44% of all
new cases registered. There were 49,677 people who started treated for some sort of kidney
failure due to diabetes alone. Another shocking number is in 2011, 228,924 people of all
ages with kidney failure due to diabetes were living on chronic dialysis or with a kidney
transplant. According to the Renal Data System between 1990 and 2006, there was an
increase of about 9% per year in end stage renal disease (ESRD). The population sample
was of Caucasian’s in the USA aged 20 to 49 years old with T1DM predominant diabetes
type and almost the exclusive type. The patients developed ESRD as a result of having at
least 15 years or sufficient duration of diabetes. Incident cases of ESRD attributed to
diabetes numbered 3,359 in 1990, 3,972 in 1995, 4,287 in 200 and 4,600 in 2006.78
Another complication associated with diabetes is hypertension. Hypertension is
high blood pressure in the blood vessels that has a force greater than normal. Continues
high pressure can strain the heart, damage the walls of the blood vessels, and increase risk
of heart attack, stroke, kidney problems and death. From 2009 to 2012, adults of age 18
years and older, 71% had blood pressure greater than or equal to 140/90 mmHg (normal
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<120/80 mmHg) or used prescription medications to control high blood pressure.72 In fact,
vascular complications are found to have an effect not only on the peripheral organs but
also on cerebral circulation. The elasticity of smooth muscle cells is decreased with chronic
hyperglycemia thus reducing the ability of blood vessels to maintain sufficient blood and
nutrient supply to the brain tissue. Patients with T2DM and hypertension as a conjugate
diagnosis showed a decreased in cortical gray matter thickness and cerebrovascular
reactivity in a spatially overlapping region of the occipital lobe compared to healthy agematched controls with just hypertension. Impact of these regions have shown a decrease in
cognitive thinking thus making prevention and control of diabetes an even more important
factor.79
Along with hypertension, dyslipidemia was diagnosed in 65% of patients with
blood low density lipid (LDL) cholesterol greater than or equal to 100 mg/dL or used
cholesterol-lowering medications who were 18 years and older from 2009 to 2012.72
Normal level of LDL should be <100 mg/dL, (high density lipid) HDL should be <40
mg/dL and triglycerides should be <150 mg/dL. Diabetic dyslipidemia is where the fasting
and postprandial triglycerides are elevated, low HDL-cholesterol, elevated LDLcholesterol and the predominance of small dense LDL particles. This causes a 2 to 4 time
increase risk of stroke and death from heart disease (increase in cardiovascular disease
(CVD)) in patient with diabetes compared to non-diabetic patients. When insulin is
produced in insufficient quantity, very low-density lipoprotein (VLDL) is increased as a
main transporter of fasting triglycerides. Insulin suppresses lipolysis in adipose tissues by
inhibiting the activity of hormone sensitive lipase, which catalyzes the mobilization of free
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fatty acids from stored triglycerides, which act as substrates and regulatory factors for
VLDL assembly and secretion.80
Overall, insulin is involved at all stages of VLDL production and secretion. Also,
in the liver, insulin inhibits the transcription of microsomal triglyceride transfer protein,
which in turn transfers triglycerides to nascent apolipoprotein B (apoB), which is the
predominant surface protein of VLDL. When insulin is insufficient, liver increases the
production of free fatty acid for energy which leads to decreased degradation of apoB, thus
causing an overproduction of VLDL. As these VLDL molecules increase, they cause a
cascade of events that leads to reduced HDL and increased small dense LDL levels.80
CVD due to dyslipidemia and thus the death rates related to CVD were increased
by 1.7 times from 2003 to 2006 among adults aged 18 years or older with diagnosed
diabetes than among adults without diagnosed diabetes. Under CVD falls heart attacks and
stroke. In 2010, hospitalization rates for heart attack were 1.8 times and stroke
hospitalization rates were 1.5 times higher among adults aged 20 years or older with
diagnosed than among adults without diagnosed diabetes. People with diabetes also had
blindness and eye problems. In 2005 to 2008, of adults with diabetes aged 40 years or older,
4.2 million (28.5%) people had diabetes retinopathy, which is damage to the small blood
vessels in the retina that may result in loss of vision.72
Some of the pharmacotherapies for diabetes treatment include the following
categories: sulfonylureas, meglitinides, biguanides thiazolidinediones, sodium-glucose
cotransporter 2 (SGLT2) inhibitors, alpha-glucosidase inhibitor, glucagon-like peptide-1
analogs and dipeptidyl peptidase-4 (DPP-IV) inhibitors. The main focus of this research
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will be on the inhibition of DPP-IV enzyme to treat T2DM but before that it’s imperative
to know the other ways of controlling diabetes.
Sulfonylureas and meglitinides class of drugs. These class of drugs interact with
the sulphonylurea receptor (SUR) 1 (an integral component of pancreatic KATP channels)
and close the adenosine triphosphate-sensitive potassium (KATP) channels in the pancreas.
The blocking of KATP channels causes voltage-dependent Ca2+ channels (VDCCs), eliciting
Ca2+ influx and a rise in intracellular Ca2+ that stimulates exocytosis of the insulincontaining secretory granules.81 The only problem with blocking the KATP channels and
increasing insulin is that these channels are also present in the coronary vascular smooth
muscle cells and cardiomyocytes, but here the SUR components are of the SUR 2A and
SUR 2B subtypes, respectively. The normal function of these channels in the heart are for
adaptation to stress and have a central role in the signaling cascades underlying myocardial
ischemic preconditioning and the cardiac responses to systolic overload. Thus, stimulation
of such reactions by blocking the KATP channels in the heart can cause a response of a
failing heart and can result in increased cardiovascular death.82
It has been shown that when sulfonylurea-induced and meglitinide-induced insulin
secretion in pancreatic beta cells exposed chronically, there is reduced insulin content and
a reduced number of functional KATP channels on the plasma membrane, as well as
accelerated apoptotic beta cell death. These two groups of drugs thus might not be as
effective when used over time as it can cause impaired acute inusinotropic action of these
agents.81 Currently there are 3rd generation sulfonylureas and several meglitinide class of
drugs available that are approved by the FDA.
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Biguanides class of drugs. This class refers to the group of drugs that control blood
glucose level by decreasing amount of blood sugar produced by the liver, decreasing
amount of sugar absorbed by the intestines and restoring body’s sensitivity to insulin. There
is only one drug approved in this class which is metformin. Metformin is used primarily to
treat T2DM but can be used to treat T1DM in combination with other therapeutics like
insulin. Metformin decreases blood glucose levels by routes other than pancreatic
mechanisms. Metformin increases body’s sensitivity to insulin and decreases rate of
gluconeogenesis and small effect on glycogenolysis which in turn reduces the amount of
blood glucose in the body helping control diabetes. Metformin is known to activate enzyme
adenosine monophosphate kinase (AMPK) which inhibits key enzymes involved in
gluconeogenesis and glycogen synthesis in the liver while also stimulating insulin
signaling and glucose uptake by transporters in muscles. Metformin usually does not cause
hypoglycemia which makes this class of drug a good choice. Metformin can cause serious
side effect of lactic acidosis which is known to cause dizziness, severe drowsiness, muscle
pain, tiredness, and other systemic symptoms, however, data has shown that these adverse
effects are minute compared to the positive effects of metformin thus it is rarely
discontinued from a patient’s medication regimen.83
SGLT2 inhibitor class of drugs. Another class of prescription for controlling
diabetes is SGLT2 inhibitors. SGLT is known to reabsorb glucose in the kidney and thus
inhibiting it leads to excretion of glucose in the urine, hence decreasing plasma glucose
level helping control diabetes. There are six active variants from SGLT1 to SGLT6,
however, two types, SGLT1 and SGLT2, with SGLT1 (10% glucose reabsorption in
kidneys) predominately expressed in intestine, kidney, heart, and skeletal muscle, and
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SGLT2 (90% glucose reabsorption in kidneys) is exclusively expressed in kidney.84,85
Under normal physiological conditions, 180 g of glucose is filtered through the kidneys
daily and all of it is reabsorbed into the circulation by SGLT’s. SGLT transport sodium
and glucose into the cells using Na+/K+ ATPase pumps followed by glucose being further
passively transported into the interstitium by GLUT-2.84 Inhibition of SGLT2 improves
hyperglycemia along with caloric and weight loss, small decreases in blood pressure and
key property of low incidence of hypoglycemia due to insulin-independent mechanism of
action. There are side effects like increased urinary and genital tract infections, diabetic
ketoacidosis, skeletal effects (disruption of homeostasis of calcium and phosphorus), and
some excess of bladder cancers seen exclusively with treatment using dapagliflozin.85
Currently three compounds are approved for use which are dapagliflozin, canagliflozin,
and empagliflozin.
Thiazolidinediones class of drugs. The thiazolidinediones are peroxisome
proliferators-activated receptor γ (PPAR-γ) agonists that alter the transcription of genes
influencing carbohydrate and lipid metabolism. Patients who are at the risk of prediabetes
can take thiazolidinediones to slow down the development of T2DM and patients who are
diagnosed with T2DM can take thiazolidinediones to improve glycemic control. However,
the use of thiazolidinediones is advised as a cautionary since the side effects are great which
include body-weight gain, congestive heart failure, bone fractures and possibly bladder
cancer. This led to warnings and eventually restrictions on the use of rosiglitazone in the
U.S. by the FDA.86 Some of the members of thiazolidinediones include rosiglitazone,
pioglitazone, lobeglitazone and troglitazone.

71

Alpha-glucosidase inhibitor class of drugs. Alpha-glucosidase inhibitors are
effective against T2DM by controlling the post-prandial hyperglycemia. The enzyme
responsible for absorbing the glucose in the intestine is alpha-glucosidase. This enzyme is
a typical exo-type glycosidase enzyme that catalyzes the releases of alpha-glucosides from
the non-reducing end of carbohydrates. It’s one of the key enzyme involved in absorbing
glucose in the intestine after a meal. So, by inhibiting alpha-glucosidase, glucose can be
reduced and thus can be effective in the treatment and management of hyperglycemia and
hyperlipidemia. However, alpha-glucosidase inhibitors are known to cause various side
effects, such as flatulence, diarrhea, and abdominal discomfort.87 Some of the drugs under
this class are miglitol, acarbose and voglibose.
GLP-1 analogs class of drugs. GLP-1 analogs are another possibility of treatment
of T2DM since in vitro and animal studies have reported that GLP-1 is associated with
multiple positive effects on pancreatic beta cells. It has also been reported that GLP-1
regulates the expression of beta cell specific genes, regulates beta cell mass by inhibiting
beta cell apoptosis and preventing beta cell glucolipotoxicity thus improved beta cell
function.88 The incretins are also responsible for improving the heart and endothelium.
Incretins decrease CV risk markers, infarct size, atherosclerosis, endothelial
dysfunction/inflammation and endoplasmic reticulum (ER) stress.89 They also signal the
brain to decrease food intake and increase cognitive function. Incretins are also helpful in
increasing bone calcium levels and increasing glucose uptake in muscle cells indirectly.
They are also shown to decrease gastric emptying which can help keep blood glucose levels
from spiking rapidly causing hyperglycemia.90
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Since GLP-1 plays an important physiological role in the body to control
hyperglycemia along with other actives, it was a good pharmaceutical candidate to create
analogs that mimicked GLP-1 peptide. Usually, GLP-1 peptide along with GIP is
inactivated in T2DM by DPP-IV enzyme (discussed in greater detail below) making them
useless in maintaining blood glucose homeostasis. These are naturally occurring hormones
that are secreted in response to glucose ingested after a meal. These hormones are
responsible for the incretin effect with more insulin secretion when ingested rather than
taken intravenously. Some of the approved analogs for GLP-1 agonists are exenatide,
liraglutide, lixisenatide, albiglutide and taspoglutide.
Recent research depicts the details of the pathophysiology of the disease showing
that there is an intricate interaction of hormonal (hormones of the pancreas) and neural
stimuli which are involved in the regulation of plasma glucose and maintaining
homeostasis.75 With the development of the enteroendocrine hormone equivalents and
other compounds, which raise the concentration of these incretin hormones by delaying
their degradation or by binding to their receptors, seem to aid in achieving a balance for
the glycemic control.91
These incretin hormones are deactivated by DPP-IV in the body. The rapid
degeneration of GLP-1 by DPP-IV enzyme dramatically reduced its action making it less
effective. With advance in research there has been two ways found to work with this
problem. One is the development of a mimic of the incretin GLP-1 (discussed above)
resistant from degradation by DPP-IV enzyme and second is the development of the DPPIV inhibitor (discussed next).75,92
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DPP-IV enzyme inhibitor class of drugs. DPP-IV, EC 3.4.14.5, is an enzyme first
described in 1967 as multifunctional membrane-anchored serine ectopeptidase belonging
to the α,β-hydrolases (family S9B) and sequentially related to prolyl oligopeptidase (POP).
The human 110 KDa DPP-IV is a 766-amino acid transmembrane glycoprotein consisting
of mainly three parts: a cytoplasmic tail (residues 1-6), a transmembrane region (residues
7-28) and an extracellular part (29-766). It is the extracellular region that is responsible for
cleaving incretin hormones. Specifically, it is residues 508 to 766 that have a catalytic triad
Ser630-Asp708-His740 and α/β-hydrolase fold and other eight-bladed β-propeller chain
(residues 56-497) which also contributes to the inhibitor binding site. DPP-IV is secreted
as a monomer but forms a dimer which is responsible for the proteolytic activity as seen in
Figure 23 using computational modeling. DPP-IV cleaves peptide/substrate after the 2nd
amino acid from the N-terminal end, specifically if the 2nd amino acid is alanine (like in
GLP-1) or proline.90 The catalytic site lies in a large cavity between the two extracellular
domains and can be accessed through two active site openings as seen in Figure 23.93
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Figure 23. Molecular modeling of DPP-IV enzyme that is observed as a homodimer. Image
using NGL viewer with UniProt P27487 from www.rcsb.org.94,95

DPP-IV inhibition prevents the inactivation of GLP-1, which increases levels of
active GLP-1. As mentioned above, this effect increases insulin secretion and reduces
glucagon secretion, thereby lowering blood glucose levels92 It has been estimated that
incretin hormones increase insulin response by 66% after an oral glucose administration96
GLP-1 is a 36-amino-acid peptide produced by the L cells, which are localized
predominantly in the lower part of the small intestine. In GLP-1 secretion, which is released
minutes after meal ingestion; fats, carbohydrates and proteins all alike have the same
stimulator effect. GIP is a 42—amino-acid peptide produced mainly by the K cells, which
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are located mainly in the duodenum. GIP is stimulated by fat and carbohydrates, whereas
protein does not stimulate GIP as much.90,97
Both GLP-1 and GIP are inactivated minutes after secretion (half-life in the order
of 1 to 2 minutes) by DPP-IV. The use of DPP-IV inhibitors like sitagliptin and vildagliptin
have clinically proven to significantly reduce HbA1c and offer many potential advantages
over existing therapies which includes a lower risk of hyperglycemia, no weight gain along
with no problems of gastrointestinal intolerance.75 In some of the animal studies,
administration of DPP-IV inhibitors depicted a long life of up to 5 hours and an inhibition
of more than 90% of plasma DPP-IV. When tested on T2DM patients, DPP-IV inhibitors
showed a potent and long-lasting inhibition soon after its intake. Some other studies
experimented with sitagliptin or vildagliptin also showed results depicting a significant
increase of GLP-1 plasma levels.91 It has been shown that inhibition of DPP-IV increases
the prandial levels of active GLP-1 approximately three-fold, from about 5-6 pmol/L to 1520 pmol/L.71
When preclinical studies were administered using DPP-IV inhibitors, selective
inhibition of DPP-IV was acceptable at the safety and tolerability criteria as compared to
two other human dipeptidyl-peptidases DPP8 and DPP9 which belong to the same family
as DPP-IV (post-proline serine peptidases). A study by Lankas et al.98 showed that both
DPP8 and DPP9 are very weak inhibitors with data showing very low affinity as compared
to DPP-IV, which displayed highest selectivity. Acute toxicity in rodents was reported with
inhibition of enzymes DPP8 and DPP9 so in order for a compound to be an effective DPPIV inhibitor, the compound must show low affinity towards DPP8 and DPP9 and high
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affinity towards DPP-IV. Thus, a lack of DPP8 and DPP9 inhibitory activity should be
absent for the development of DPP-IV as an effective and safe antidiabetic therapy.75,99
DPP-IV is also known as the T-cell antigen CD26, and is a cell-surface protease
localized in numerous sites, including the kidney and intestinal brush-border membranes
as well as on hepatocytes. DPP-IV is also found throughout the entire vascular bed, located
on endothelial cells as well as in a soluble form in plasma.100 It is also widely distributed
in kidney, liver, intestine, spleen, adrenal glands, lymphocytes, endothelial cells and
placenta.93 Not only is DPP-IV used to cleave integrins, but it is also used to metabolize
neuropeptide Y, peptide YY, gastrin-releasing polypeptide, pituitary adenylate-cyclaseactivating polypeptide, insulin-like growth factor-1, substance P and various chemokines.
Metabolism and activation of peptide YY and neuropeptide Y which are involved in GI
functions and regulation of food intake and obesity can be associated to the contributing
factors of T2DM.75 The following activities of DPP-IV show that it is involved in other
homeostatic mechanisms like neurogenic inflammation, blood pressure and the immune
system.90
The available FDA approved drugs for inhibiting DPP-IV enzyme are as follows;
sitagliptin, vildagliptin, saxagliptin, alogliptin and linagliptin. Sitagliptin was used as a
control in our research, which is sold as the brand name Januvia. Sitagliptin phosphate
monohydrate

is

described

chemically

as

7-[(3R)-3-amino-1-oxo-4-(2,4,5-

trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3a]pyrazine phosphate (1:1) monohydrate [C16H15F6N5O•H3PO4•H2O] with the R
enantiomer being the active form of Januvia. Pharmacophore of sitagliptin is the 3(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4.3-a]pyrazine as shown in Figure 24
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labeled sitagliptin binding region (SBR) with DPP-IV enzyme. There are two other
pharmacophore sites on sitagliptin that are labeled common binding region (CBR) with
DPP-IV enzyme. The amino acids associated with SBR are serine (S), phenylalanine (F),
and arginine (R) at positions, 209, 357, and 358, respectively. The serine and arginine are
both donating hydrogens to trifluromethyl and triazole, respectively. The phenylalanine is
involved in pi-pi interactions with the aromatic ring. The other amino acids involved are
glutamic acids (E) at position 205 and 206 and tyrosine (Y), valine (V), tryptophan (W),
tyrosine (Y), aspartic acid (D) and tyrosine (Y) at positions 631, 656, 659, 662, 663 and
666, respectively, on DPP-IV enzyme (Figure 24).101
Based on current literature and structural requirements for a compound to be a DPPIV inhibitor, we were able to synthesize a lead compound that showed inhibitory activity.
This lead compound was further used to build a library of DPP-IV inhibitors via structural
activity relationship via in vitro DPP-IV enzymatic inhibition assays.
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(a)

(b)
Figure 24. Molecular modeling of DPP-IV enzyme in complex with inibitors. (a) β-amino
acid inhibitor and (b) amino acid residue interaction of DPP-IV enzyme with drug
Sitagliptin.94,95
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Chapter 4
Characteristic of DPP-IV Inhibitors and their Validation via In Vitro DPP-IV
Enzymatic Assay
Novel Compounds Containing Cyanopyrrolidine and β-amino Alcohols Scaffolds
Inhibitors of DPP-IV required specific structural groups to prevent the function of
this enzyme. Cyanopyrrolidinyl β-amino alcohols are novel scaffolds with potential for a
wide array of pharmacological properties. These scaffolds were selectively accessed from
simple and inexpensive commercially available chemicals in few synthetic steps with
minimal purification. A 36-compound library of these scaffolds were provided to be
examined as DPP-IV inhibitors.102
Cyanopyrrolidines are molecular scaffolds that are highly recurrent among natural
products and commercial drugs. The scaffold has shown affinity to dipeptidyl peptidases
as a proline mimetic group and it has been hypothesized that the activity arises from a
transient covalent interaction of the nitrile with S630 that triggers a slow dissociation from
the enzyme. Thus, most of the most potent DPP-IV inhibitors contain this scaffold
(vinagliptin, saxagliptin, vildagliptin). Cyanopyrrolidines can be easily obtained from
naturally available proline and many synthetic approaches are available. However, despite
the diversity of methods many lack scalability and reproducibility.102
β-Amino alcohols are an important class of compounds in medicinal chemistry and
drug discovery due to their high occurrence in commercially available drugs. They often
behave as β-adrenergic blockers, widely used in the management of cardiovascular
disorders, including hypertension, anginapectoris, cardiac arrhythmias, and other disorders
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related to the sympathetic nervous system. Amino alcohols have also been used as protein
kinase C inhibitors, glycosidase inhibitor and antimalarial agents. Among commercial
drugs, this scaffold is present in Oxycontin, Coreg, and Toprol-XL. Other pharmaceutical
drugs such as Zyvox and Skelaxin feature oxazolidones that can be formed through amino
alcohol precursors. Moreover, these can be used as chemical synthons for the synthesis of
more complex heterocyclic scaffolds. Thus, a novel family of inhibitors that shares the
cyanopyrrolidine and β-amino alcohol scaffolds towards more potent and selective diabetes
therapeutics were created and tested.102
Research Design and Methods
General Method A: Synthesis of mono-alkylated amino alcohols. In a 20 mL
vial at room temp., epoxide (1.0 mmol, 1.0 equiv.) and amine (1.5 mmol, 1.5 equiv.) were
added to 6.7 mL of DMF. The reaction was stirred at 60 °C for 12 h at which point the rxn
mixture received deionized water (50 equiv.). The reaction was allowed to stir at 60 °C for
an additional 12 h. The resulting crude was stripped of solvent and the residue loaded
directly onto a silica gel column for purification.102
General Method B. Synthesis of double-alkylated amino alcohols. In a 20 mL
vial at room temp., epoxide (2.0 mmol, 2.0 equiv.) and amine (1.0 mmol, 1.0 equiv.) were
added to 5 mL of deionized water. The reaction was stirred at room temp. for 12 h. The
resulting crude was stripped of water and the residue loaded directly onto a silica gel
column for purification.102
Compounds. (2S)-1-((2-hydroxy-2-phenylethyl)glycyl)pyrrolidine-2-carbonitrile
(1aa): 2-((2-hydroxy-2-phenylethyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (1ab): (2S)-181

(bis(2-hydroxy-2-phenylethyl)glycyl)pyrrolidine-2-carbonitrile (1ba): 2-(bis(2-hydroxy2-phenylethyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (1bb): (2S)-1-((2-(4-fluorophenyl)2-hydroxyethyl)glycyl)pyrrolidine-2-carbonitrile (2aa): (2S)-1-((2-(4-chlorophenyl)-2hydroxyethyl)glycyl)pyrrolidine-2-carbonitrile

(3aa):

hydroxyethyl)glycyl)pyrrolidine-2-carbonitrile

(2S)-1-((2-(4-bromophenyl)-2-

(4aa):

hydroxyethyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one

2-((2-(4-bromophenyl)-2(4ab):

(2S)-1-(bis(2-(4-

bromophenyl)-2-hydroxyethyl)glycyl)pyrrolidine-2-carbonitrile (4ba) (Figure 4.9): 2(bis(2-(4-bromophenyl)-2-hydroxyethyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one

(4bb):

(2S)-1-((2-hydroxy-3-phenoxypropyl)glycyl)pyrrolidine-2-carbonitrile

2-((2-

(5aa):

hydroxy-3-phenoxypropyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (5ab): (2S)-1-(bis(2hydroxy-3-phenoxypropyl)glycyl)pyrrolidine-2-carbonitrile (5ba): 2-(bis(2-hydroxy-3phenoxypropyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (5bb): (S)-1-(((S)-2-hydroxy-3phenoxypropyl)glycyl)pyrrolidine-2-carbonitrile

(6aa):

(S)-2-((2-hydroxy-3-

phenoxypropyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (6ab): (S)-1-(bis((S)-2-hydroxy-3phenoxypropyl)glycyl)pyrrolidine-2-carbonitrile

(6ba):

2-(bis((S)-2-hydroxy-3-

phenoxypropyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (6bb): (2S)-1-((2-hydroxy-3-(otolyloxy)propyl)glycyl)pyrrolidine-2-carbonitrile

(7aa):

2-((2-hydroxy-3-(o-

tolyloxy)propyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (7ab): (2S)-1-(bis(2-hydroxy-3(o-tolyloxy)propyl)glycyl)pyrrolidine-2-carbonitrile

(7ba):

2-(bis(2-hydroxy-3-(o-

tolyloxy)propyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (7bb): (2S)-1-((3-(benzyloxy)-2hydroxypropyl)glycyl)pyrrolidine-2-carbonitrile

(8aa):

2-((3-(benzyloxy)-2-

hydroxypropyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (8ab): (2S)-1-(bis(3-(benzyloxy)2-hydroxypropyl)glycyl)pyrrolidine-2-carbonitrile
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(8ba):

2-(bis(3-(benzyloxy)-2-

hydroxypropyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one (8bb): (2S)-1-((2-hydroxy-3-(4methoxyphenoxy)propyl)glycyl)pyrrolidine-2-carbonitrile

(9aa):

methoxyphenoxy)propyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one

2-((2-hydroxy-3-(4-

(9ab):

(2S)-1-(bis(2-

hydroxy-3-(4-methoxyphenoxy)propyl)glycyl)pyrrolidine-2-carbonitrile (9ba): 2-(bis(2hydroxy-3-(4-methoxyphenoxy)propyl)amino)-1-(pyrrolidin-1-yl)ethan-1-one

(9bb):

(2S)-1-((3-(4-fluorophenoxy)-2-hydroxypropyl)glycyl)pyrrolidine-2-carbonitrile (10aa):
(2S)-1-((3-(3,4-difluorophenoxy)-2-hydroxypropyl)glycyl)pyrrolidine-2-carbonitrile
(11aa):

(2S)-1-((2-hydroxy-3-(3,4,5-trifluorophenoxy)propyl)glycyl)pyrrolidine-2-

carbonitrile (12aa): (2S)-1-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)glycyl)pyrrolidine2-carbonitrile
carbonitrile

(13aa):

(2S)-1-((2-hydroxy-3-phenylpropyl)glycyl)pyrrolidine-2-

(14aa):

and

(2S)-1-((3-(furan-2-ylmethoxy)-2-

hydroxypropyl)glycyl)pyrrolidine-2-carbonitrile (15aa).
In vitro assay. The enzymatic inhibition of DPP-IV was measured in vitro by the
endpoint fluorometric assay using substrate Gly-Pro-AMC (MW: 329.4). The enzyme
cleaves the bond between Pro-AMC thus releasing the fluorescent aminomethylcoumarin
(AMC) resulting in an increase in fluorescence intensity. The inhibitors, DPP-IV enzyme
and substrate were dissolved in the 100 mM HEPES buffer (pH 7.5, 0.1 mg/ml BSA).
Inhibitor stock concentration was dissolved in 100% DMSO followed by working serial
dilution starting at 1% DMSO. The final concentrations of enzyme and substrate used were
0.003 ng/µL and 50 µM, respectively.
The assay was performed in an 384-Well plate (from BD Falcon, catalog # 353232,
well 120 µL assay plate white, standard surface, nonsterile) with final volume of 100 µL
in all wells. All samples were assayed in triplicates. A background well was created with
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10 µL of Gly-Pro-AMC (from MP Biomedicals, LLC, catalog # AMC039) substrate plus
90 µL buffer; a 100% activity well was created with 10 µL of DPP-IV enzyme (from
Sigma-Aldrich, Inc., catalog # D7052) and 10 µL of Gly-Pro-AMC substrate plus 80 µL
buffer; and inhibitor wells were created with 10 µL of DPP-IV enzyme, 10 µL of inhibitor
and 10 µL Gly-Pro-AMC substrate plus 70 µL buffer. The order of the addition to the well
was buffer, enzyme, inhibitor and finally the substrate to initiate the reaction. The plate
was covered and centrifuged for 30 seconds at 800xg followed by incubation for 30 mins
at 37° C. The fluorescence was the measured on the SpectraMax M5 with excitation
wavelength of 360 nm and emission wavelength of 460 nm with an auto cut-off wavelength
setting on the instrument at 37° C. IC50 values were analyzed using Graphpad Prism 6 by
a fit of reaction rates to a four-parameter Hill equation by nonlinear regression. Equation
used to calculate IC50:
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
Where IC50 is the concentration (same unit as X) of inhibitor that gives a response half
way between Bottom and Top (plateaus in the units of the Y). HillSlope describes the
steepness of the family of curves. A HillSlope of -1.0 was used.
Results and Discussion
Two different series were created, cyano (mono-alkylated (aa) and doublealkylated (ba)) and descyano (mono-alkylated (ab) and double-alkylated (bb)). Table 2
shows series 1 to 9 and Table 3 shows series 10 to 15 of DPP-IV inhibitor. It can be seen
from series 10 to 15 that ab, ba, and bb were not synthesized as the Structural Activity
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Relationship (SAR) from series 1 to 10 showed no activity for compounds containing these
characteristics.
It was anticipated that series aa would establish the baseline activity for these
inhibitors and that is what was observed as aromatic cyanopyrrolidinyl amino alcohols
demonstrated to have significant potency (IC50 under 0.2 uM). All mono-alkylated
compounds with cyano group aa showed greater activity than all double-alkylated bb
series. It was observed that analogue 1aa (42 nM) (Figure 25) had significant more
inhibition

against

DPP-IV

than

the

other

substituted

aromatic

analogues

(2aa, 3aa and 4aa) (Figure 26) where the epoxide used was styrene oxide. Moreover, from
those the p-fluorophenyl analogue 2aa (6511 nM) surprisingly displayed much lower
inhibition followed by p-chlorophenyl 3aa (123.5 nM), then p-bromophenyl 4aa (121.6
nM) and highest activity when there was no substitution 1aa (42.19 nM). What was
surprising was 4ba (129.6 nM) showed similar IC50 to 4aa analog along with some activity
in descyano mono-alkylated 4ab (1299 nM) and no activity for descyano double-alkylated
4bb (Figure 27). Compounds in entry 4 containing bromine on the aromatic were the only
series that showed activity in ba and ab series as all other compounds containing ba and
ab series showed >10K nM IC50.
Phenylgylcidyl ethers were used to react with amino alcohol series and it was found
that the respective cyanopyrrolidine amino alcohols were obtained in great yields and as
single isomers (Table 1, Entry 5). The resulting amino alcohols were obtained as mixtures
of diastereomers at the alcohol and cyano centers, but due to their remote relationship, they
are seen as one isomer by NMR spectroscopy. Despite the remoteness between the chiral
centers on the proposed target, we anticipated that we might need to construct this scaffold
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as a single diastereomer to validate the effect of the remote chiral center. Thus, (S)phenylglycidyl ether was reacted with the amine series to get products (Table 1, Entry 6).
The scaffold remote relationship between its chiral centers suggested that as a mixture of
diastereomers, the scaffold inhibition would be potentially comparable. We corroborated
this hypothesis as we found that the inhibitory activity of 5aa (91.02 nM) (mixture of
diastereomers) (Figure 28) was very similar to the enantiopure amino alcohol 6aa (81.72
nM) (Figure 29). The introduction of phenoxy ethers is known to enhance activity among
several β-adrenergic blockers
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. Consequently, we found the SAR of phenoxy in series

5aa and 6aa, o-methylphenoxy in 7aa (98.93 nM) (Figure 30), benzyloxy in 8aa (80.24
nM) (Figure 31) and p-methoxy in 9aa (74.32 nM) (Figure 32) to have similar inhibitory
properties as to the previous analogues but failed to improve 1aa activity.
Based on the current SAR data found, we envisioned that introducing fluorine
atoms on the phenoxy group might further increase the inhibitory properties. We found
that p-fluorophenoxy 10aa (112.6 nM) had comparable activity. Moreover, 4,5difluorophenoxy 11aa (77.96 nM) proved to be more active (analogues to SAR from
reported studies), but 4,5,6-trifluorophenoxy 12aa (141.19 nM) proved to decrease the
inhibitory activity. Figure 33 shows the dose-response curve comparing the number and
placement of fluorine on the phenoxy group. Further assessment of the SAR demonstrated
that naphthyl cyanopyrrolidinyl amino alcohol 13aa (100.6 nM) is comparably active.
Interestingly, removing the oxygen from the benzyloxy analogue 14aa (2680 nM) fully
drops DPP-IV activity. Low activity from heterocyclic analogue 15aa (>10K nM) further
proved the need for a more lipophilic side chain.102 Figure 34 displays the dose-response
curve comparing analogous compounds 13aa, 14aa and 15aa.
86

It was found that the remaining analogues had significantly lower inhibitory
activity. Moreover, Series ab/bb also failed at providing significant activity against DPPIV. The SAR data from this preliminary biochemical study shows that analogue 1aa is the
most active (42 nm), and analogues that introduce complexity around the phenyl ring have
comparable inhibitory properties. It has been demonstrated that the monoalkylated scaffold
is by far the most active scaffold. Despite reported evidence of a potential decomposition
pathway through an acid-catalyzed intramolecular cyclization, stability studies displayed
complete structural stability for the inhibitor against analogous conditions. This study also
has shown that fluorine incorporation can improve activity, but does not play a significant
role as seen in other DPP-IV inhibitors.102
Conclusion
Novel cyanopyrrolidinyl β-amino alcohols were derived and successfully tested in
vitro against DPP-IV enzyme. All of the mono-alkylated amino alcohols showed greater
activity than all of the double-alkylated amino alcohols against DPP-IV enzyme. It was
also shown that all compounds that contained the cyano group on the pyrrolidinyl amine
showed greater activity than compounds without the cyano group. Compounds containing
phenyl glycidyl ethers showed greater activity than styrene oxides. When styrene oxide
was substituted with halogens, bromine showed activity greater than chlorine followed by
fluorine; however, no substitution showed the greatest activity. When fluorine was
substituted on the phenyl glycidyl ether, it was found that para substitution was favored
followed by meta which was better than no substitution. It can also be concluded from the
SAR that a lipophilic side chain is more favored over a hydrophilic side chain on the
epoxide.
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Since these novel molecules contain the β-amino alcohols, the next step is to test
them against β-adrenergic receptors as potential β-blockers which would make these
compounds a dual acting drug that would be beneficial in maintenance of diabetes and
hypertension. Also, since literature has shown toxicity to the animal when enzymes DPP8
and 9 were inhibited along with DPP-IV, it is important for these compounds to be tested
against DPP8 and 9 enzymes as it will help in synthesizing a more potent secondgeneration library of DPP-IV inhibitors. Not only is activity against DPP8 and 9 important
for second-generation library, but it is important so that these molecules can be further
studied in vivo.
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SAR activity of compounds 1 to 9.102

Table 2
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SAR activity of compounds 10 to 15.102

Table 3
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Figure 25. Dose-response curve showing IC50 of compounds 1aa, 1ab, 1ba, and 1bb. The values represent the mean ± S.E.M
(n=3)
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Figure 26. Dose-response curve showing IC50 of compounds 1aa, 2aa, 3aa, and 4aa. The values represent the mean ± S.E.M
(n=3)
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Figure 27. Dose-response curve showing IC50 of compounds 4aa, 4ab, 4ba, and 4bb. The values represent the mean ± S.E.M
(n=3)
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Figure 28. Dose-response curve showing IC50 of compounds 5aa, 5ab, 5ba, and 5bb. The values represent the mean ± S.E.M
(n=3)
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Figure 29. Dose-response curve showing IC50 of compounds 6aa, 6ab, 6ba, and 6bb. The values represent the mean ± S.E.M
(n=3)
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Figure 30. Dose-response curve showing IC50 of compounds 7aa, 7ab, 7ba, and 7bb. The values represent the mean ± S.E.M
(n=3)
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Figure 31. Dose-response curve showing IC50 of compounds 8aa, 8ab, 8ba, and 8bb. The values represent the mean ± S.E.M
(n=3)
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Figure 32. Dose-response curve showing IC50 of compounds 9aa, 9ab, 9ba, and 9bb. The values represent the mean ± S.E.M
(n=3)
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Figure 33. Dose-response curve showing IC50 of compounds 10aa, 11aa, and 12aa. The values represent the mean ± S.E.M
(n=3)
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Figure 34. Dose-response curve showing IC50 of compounds 13aa, 14aa, and 15aa. The values represent the mean ± S.E.M
(n=3)

Chapter 5
Summary Remarks
Peanut Allergies
Problem of peanut allergenicity was investigated since the rate of prevalence and
burden on the western world has increased in recent decade. We looked to find a solution
that would alleviate majority of people allergic to peanuts in the most efficient way. Since
majority of allergic reactions are due to macromolecule protein, we looked to manipulate
proteins of peanut, specifically Ara h2, since it has been shown in literature that IgE to Ara
h2 has been found in majority of people allergic to peanut. Before we could manipulate
Ara h2, we needed great amounts of protein to work with in an efficient manner. Thus, we
were able to come up with a novel purification method that allowed us to purify Ara h2
efficiently.
After having sufficient amount of Ara h2 to work with, we had the task of
modifying the protein without completely destroying it. We looked to mask various
epitopes of Ara h2 by cross-linking the proteins together using various cross-linkers that
included BS3, DST, EDC, Sulfo-EGS and BM[PEG]3. These cross-linkers were utilized
according to literature and cross-linked with Ara h2 at various conditions that manipulated
temperature, pH and native/reduced form of protein. After cross-linking, protein was
visualized on SDS-PAGE gels for visual confirmation of polymerization of the protein,
which was negative. On various cross-linkers, as concentration of cross-linker was
increased, there was disappearance of protein as seen on the lanes of SDS-PAGE gel. This
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could have been due to the insolubility of the newly formed cross-linked product that was
not able to dissolve in sample buffer and thus unable to be visualized on the SDS-PAGE.
Further characterizations are required to confirm if Ara h2 had not indeed been
cross-linked with various cross-linkers. One method is to determine the protein
concentration of Ara h2 in control sample compared to various concentrations of crosslinker and protein samples combined. This can be done using ELISA that includes IgG
antibodies specific to Ara h2 to see how the concentration has decreased as concentration
of cross-linker has increased. Another approach is to determine changes in the secondary
structure of Ara h2 using CD, however, with caution since Ara h2 exists as two different
isomers. If there is indeed a cross-linking between molecules of Ara h2, we should be able
to confirm this change in mass using mass spectrometry. Finally, to confirm a decrease in
allergenicity of Ara h2, ELISA or Western blot can be utilized with IgE antibodies since
these antibodies are responsible for causing allergic reaction in the body.
Overall, various cross-linkers were tested, however, more empirical proof is
required to confirm a change in structure of Ara h2 along with confirmation of decreased
binding to IgE specific to Ara h2.
Diabetes Mellitus
Diabetes is an increasing problem everywhere in the world. The number of newly
diagnosed cases of diabetes has been increasing, however, there is also an increase in new
drugs that are either in clinical trials or have been recently approved for treatment of
diabetes. We decided to look into treating diabetes, specifically type 2 diabetes by the
mechanism of inhibiting enzyme DPP-IV in the body. This enzyme is known to cleave
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incretin hormones in the body that are responsible for aiding in decreasing blood glucose
levels. It has been shown in literature that by inhibiting this enzyme in the body, it is
possible to control T2DM. However, we were interested in not just controlling diabetes but
to help people who are also diagnosed with hypertension associated with diabetes. We
wanted to synthesize novel compounds that would target DPP-IV enzyme and β-adrenergic
receptors as one compound containing two different pharmacophores targeting two
different protein structures in the body.
We were able to incorporate cyanopyrrolidine and β-Amino alcohol scaffolds to
make a novel 36-compound library. These compounds were successful tested for SAR
activity against DPP-IV enzyme in vitro assays. A series of characteristics were determined
that will now allow for synthesis of second generation library. We are in the
implementation of next step which is taking the most potent DPP-IV inhibitor compounds
and testing them against DPP8 and DPP9. We are also in the process of testing the most
potent compounds against CHO cell lines that express β-adrenergic activity in vivo assay.
This data will allow us to move into in vivo studies that would test for blood glucose levels
in murine studies along with β-adrenergic receptor blockers in the murine.
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